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A B S T R A C T
Background
Depressive disorders are the most common psychiatric comorbidity in patients with epilepsy, affecting around one-third, with a
significant negative impact on quality of life. There is concern that patients may not be receiving appropriate treatment for their
depression because of uncertainty regarding which antidepressant or class works best and the perceived risk of exacerbating seizures.
This review aims to address these issues and inform clinical practice and future research.
Objectives
We aimed to review and synthesise evidence from randomised controlled trials of antidepressants and prospective non-randomised
studies of antidepressants used for treating depression in patients with epilepsy. The primary objectives were to evaluate the efficacy
and safety of antidepressants in treating depressive symptoms and the effect on seizure recurrence.
Search methods
We conducted a search of the following databases: the Cochrane Epilepsy Group Specialised Register; the Cochrane Central Register
of Controlled Trials (CENTRAL 2014, Issue 5), MEDLINE (Ovid), SCOPUS, PsycINFO, www.clinicaltrials.gov and conference
proceedings, including studies published up to 31 May 2014. There were no language restrictions.
Selection criteria
We included randomised controlled trials (RCTs) and prospective non-randomised cohort controlled and uncontrolled studies inves-
tigating children or adults with epilepsy treated with an antidepressant for depressive symptoms. The intervention group consisted
of patients receiving an antidepressant drug in addition to an existing antiepileptic drug regimen. The control group(s) consisted of
patients receiving a placebo, comparative antidepressant, psychotherapy or no treatment in addition to an existing antiepileptic drug
regimen.
Data collection and analysis
We extracted data on trial design factors, patient demographics and outcomes for each study. The primary outcomes were changes
in depression scores (proportion with a greater than 50% improvement or mean difference) and change in seizure frequency (mean
difference or proportion with a seizure recurrence or episode of status epilepticus, or both). Secondary outcomes included the number
of patients withdrawing from the study and reasons for withdrawal, as well as any adverse events. Two authors undertook data extraction
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separately for each included study. We then cross-checked the data extraction. We assessed risk of bias using a version of the extended
Cochrane Collaboration tool for assessing risk of bias in both randomised and non-randomised studies. We presented binary outcomes
as risk ratios (RRs) with 95% confidence intervals (CIs). We presented continuous outcomes as standardised mean differences (SMDs)
with 95% CIs, and mean differences (MDs) with 95% CIs. If possible we intended to use meta-regression techniques to investigate
possible sources of heterogeneity however this was not possible due to lack of data.
Main results
We included in the review eight studies (three RCTs and five prospective cohort studies) including 471 patients with epilepsy treated
with an antidepressant. The RCTs were all single-centre studies comparing an antidepressant versus active control, placebo or no
treatment. The five non-randomised prospective cohort studies reported on outcomes mainly in patients with partial epilepsy treated
for depression with a selective serotonin reuptake inhibitor (SSRI). We rated all the RCTs and one prospective cohort study as having
unclear risk of bias. We rated the four other prospective cohort studies as having high risk of bias. We were unable to perform any meta-
analysis for the proportionwith a greater than 50% improvement in depression scores because the studies reported on different treatment
comparisons. The results are presented descriptively and show a varied responder rate of between 24% and 97%, depending on the
antidepressant given. For the mean difference in depression score we were able to perform a limited meta-analysis of two prospective
cohort studies of citalopram, including a total of 88 patients. This gave low quality evidence for the effect estimate of 1.17 (95% CI
0.96 to 1.38) in depression scores. Seizure frequency data were not reported in any RCTs and we were unable to perform any meta-
analysis for prospective cohort studies due to the different treatment comparisons. The results are presented descriptively and show
that treatment in three studies with a selective serotonin reuptake inhibitor did not significantly increase seizure frequency. Patients
given an antidepressant were more likely to withdraw due to adverse events than inefficacy. Reported adverse events for SSRIs included
nausea, dizziness, sedation, gastrointestinal disturbance and sexual dysfunction. Across three comparisons we rated the evidence as
moderate quality due to the small sizes of the contributing studies and only one study each contributing to the comparisons. We rated
the evidence for the final comparison as low quality as there was concern over the study methods in the two contributing studies.
Authors’ conclusions
Existing evidence on the effectiveness of antidepressants in treating depressive symptoms associated with epilepsy is very limited. Only
one small RCT demonstrated a statistically significant effect of venlafaxine on depressive symptoms. We have no high quality evidence
to inform the choice of antidepressant drug or class of drug in treating depression in people with epilepsy. This review provides low
quality evidence of safety in terms of seizure exacerbation with SSRIs, but there are no available comparative data on antidepressant
classes and safety in relation to seizures. There are currently no comparative data on antidepressants and psychotherapy in treating
depression in epilepsy, although psychotherapy could be considered in patients unwilling to take antidepressants or where there are
unacceptable side effects. Further comparative clinical trials of antidepressants and psychotherapy in large cohorts of patients with
epilepsy and depression are required to better inform treatment policy in the future.
P L A I N L A N G U A G E S U M M A R Y
Antidepressants for people with epilepsy and depression
Background
Depressive disorders occur in approximately one-third of people with epilepsy, often requiring antidepressant treatment. However,
depression often goes untreated in people with epilepsy, partly due to fear that antidepressants might cause seizures. There are different
classes of antidepressants, however they all aim to increase key neurotransmitters in the brain, thereby alleviating depressive symptoms.
Characteristics of studies
We carried out a search of databases on 31 May 2014. We found eight studies that included 471 patients with epilepsy treated with an
antidepressant. Three were randomised controlled trials and five were non-randomised prospective cohort studies. The studies observed
the effect of different antidepressants, mainly a class of antidepressant called a selective serotonin reuptake inhibitor (SSRI).
Results
Taking all the evidence into account, the review found that there is very limited evidence demonstrating a significant effect of an-
tidepressants on depressive symptoms in epilepsy. There was limited information on the effect of antidepressants on seizure control,
however in the studies reporting this outcome there did not appear to be any significant worsening of seizures.
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Quality of the studies
We assessed the studies with regard to bias and quality. Overall the quality of the evidence was rated as moderate for the clinical trials
and low for the non-randomised prospective cohort studies. More high quality, larger trials of antidepressants are needed to examine
how different classes of antidepressant compare and what impact they are likely to have on seizure control.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Paroxetine compared to doxepin for people with epilepsy and depression
Patient or population: people with epilepsy and depression
Settings: outpatients
Intervention: paroxetine
Comparison: doxepin
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Doxepin Paroxetine
> 50% reduction in de-
pressive symptoms
706 per 1000 819 per 1000
(621 to 1000)
RR 1.16
(0.88 to 1.52)
67
(1 study)
⊕⊕⊕©1
moderate
Only 1 study examined
the influence of paroxe-
tine versus doxepin on re-
duction in depression and
it found no significant dif-
ference between the 2
drugs
Mean depression scores
- HAMD scores
The mean HAMD depres-
sion score in the interven-
tion groups was
0.65 higher
(-2.15 lower to 3.45
higher)
67
(1 study)
⊕⊕⊕©1
moderate
In the same study no dif-
ferences were found be-
tween mean depression
scores in patients taking
paroxetine compared to
those taking doxepin
Seizure frequency - - - 0
(0 studies)
- No data contributed to
this outcome
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Withdrawals (specific
reasons)
88 per 1000 13 per 1000
(1 to 242)
RR 0.15
(0.01 to 2.74)
67
(1 study)
⊕⊕⊕©1
moderate
In this study 0 patients
withdrew from the parox-
etine group and 3 with-
drew from the doxepin
group. No significant dif-
ference was found be-
tween the 2 groups
Cognitive functioning - - - 0
(0 studies)
- No data contributed to
this outcome
Quality of life - - - 0
(0 studies)
- No data contributed to
this outcome
Adverse effects - - - 0
(0 studies)
- No data contributed to
this outcome
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; HAMD: Hamilton Rating Scale for Depression; RR: risk ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1Quality downgraded for imprecision due to only one study contributing to the outcomes and it was a small study.
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B A C K G R O U N D
Description of the condition
Depressive disorders are the most common psychiatric comorbid-
ity in patients with epilepsy (Tellez-Zenteno 2007), and they are
the strongest predictor of poor quality of life (Boylan 2004). Symp-
toms of depression include low mood, tiredness and apathy. Sleep
and cognitive functioning may also be affected. Depressive dis-
orders occur in approximately one-third of patients with epilepsy
(Baker 1996; Indaco 1992; Jacoby 1996; Mendez 1986). These
disorders are broadly divided into unipolar (depression only) and
bipolar disorders (depression associated with mania or hypoma-
nia) (American Psychiatric Association 2000). Depressive disor-
ders in epilepsy may be mediated via the interplay of neurobiolog-
ical, psychosocial and iatrogenic factors (Lambert 1999). Depres-
sive symptoms or episodes may occur inter-ictally (i.e. they appear
unrelated to seizures) or peri-ictally (preceding, during or follow-
ing seizures). This is an important distinction as patients may re-
quire modification of their antiepileptic drug regime, commence-
ment of antidepressant drug therapy, or both. In some patients
the depressive symptoms may follow a significant period of seizure
remission in previously uncontrolled epilepsy, thought to occur
via neuro-biochemical changes and termed ’forced normalisation’
(Trimble 1998). Studies examining clinical predictors of risk for
depression in patients with epilepsy have produced inconsistent
results (Lin 2012). There is a perceived greater risk of depression
in patients with temporal lobe epilepsy, although elevated rates
of depression have been found in generalised and extra-temporal
focal epilepsy (Adams 2008). Epilepsy related factors as predictors
of risk for depression are inconsistent. Psychosocial factors such as
life stress, coping style, social support, perceived stigma and per-
sonality are more consistent predictors of depression in patients
with epilepsy (Hermann 2000).
In 2008, the Food and Drug Administration issued a health alert
about an increased risk of suicidal ideation in patients taking
antiepileptic drugs (Hesdorffer 2009). This alert was based on
a meta-analysis of approximately 28,000 patients who had par-
ticipated in randomised controlled trials (RCTs) investigating 11
antiepileptic drugs. There were four completed suicides, all of
whom had taken antiepileptic drugs, compared to no cases of sui-
cide in the placebo groups (odds ratio (OR) 1.8; 95% confidence
interval (CI) 1.24 to 2.66). Since this alert, a number of obser-
vational studies have investigated the association, reporting con-
flicting results, and a recent consensus statement on risk of suicide
with antiepileptic drugs has been published by the International
League Against Epilepsy (ILAE) Commission on Neuropsychobi-
ology (Mula 2013).Whilst the exact risk of suicidewith antiepilep-
tic drugs is unknown, depression as a treatment-emergent ad-
verse effect is associated with some antiepileptic drugs (GABAer-
gic antiepileptic drugs: benzodiazepines, vigabatrin, gabapentin
and also topiramate, levetiracetam and zonisamide) (Mula 2009).
Other antiepileptic drugs appear to have mood-stabilising prop-
erties (valproic acid, lamotrigine, carbamazepine, oxcarbazepine),
which may benefit patients with epilepsy and depression. En-
zyme-inducing antiepileptic drugs (i.e. carbamazepine) may lower
plasma levels of antidepressants, thus impacting on their effective-
ness.
Case-control studies have shown that patientswith depressionhave
a two- to seven-fold higher risk of developing epilepsy, implying
a bi-directional relationship (Hesdorffer 2000; Hesdorffer 2006;
Hesdorffer 2012). There could be a number of factors to explain
this, for example shared pathophysiology involving disturbance
in several key neurotransmitter systems (Bagdy 2007), structural
lesions (frontal lobe tumours) or a genetic susceptibility. However,
there is also the possibility that the use of antidepressants may trig-
ger seizures. This is a common concern for healthcare profession-
als and may influence decisions to start antidepressant treatment
(Cotterman-Hart 2010).
Description of the intervention
Antidepressants are a heterogeneous class of drugs that have been
the mainstay of pharmacological treatment in treating depressive
disorders. There are 10 classes of antidepressants used to treat de-
pressive disorders, with 60% to 70% of depressive episodes re-
sponding to current treatment (Klerman 1990; Sackeim 2006).
These are:
1. tricyclic antidepressants;
2. selective serotonin reuptake inhibitors;
3. serotonin-norepinephrine reuptake inhibitors;
4. monoamine oxidase inhibitors;
5. serotonin/antagonist reuptake inhibitors (i.e. trazodone);
6. dopamine and norepinephrine reuptake inhibitors (i.e.
bupropion);
7. a-2 antagonists (i.e. mirtazapine);
8. norepinephrine reuptake inhibitors (i.e. reboxetine);
9. selective serotonin reuptake enhancers (i.e. tianeptine); and
10. serotonin 5HT2C receptor antagonists (i.e. agomelatine).
These drugs work by targeting serotonergic and/or noradrenergic
and/or dopaminergic neurotransmission, with the aim of increas-
ing their synaptic concentrations (Stahl 2000). Glutamate antag-
onists represent a novel class of drug currently being tested in re-
fractory depression (Zarate 2006).
The risk of seizures with antidepressants was reported in early
studies of the first-generation antidepressants, notably tricyclic an-
tidepressants (Preskorn 1992; Wroblewski 1990). Alper 2007 re-
viewed the incidence of seizures in 75,000 non-epileptic patients
in phase II and phase III trials of antidepressant treatment. It re-
ported lower incidence rates of seizures in those randomised to an
antidepressant versus placebo (standardised incidence ratio 0.48;
95% CI 0.36 to 0.61) (Alper 2007). Coupland 2011 examined
60,746 primary care patients aged 65 and over treated for depres-
sion with antidepressants between 1996 and 2007 and showed
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increased risks of epilepsy/seizures for selective serotonin reuptake
inhibitors (hazard ratio (HR) 1.80; 95% CI 1.32 to 2.43) and
other antidepressant classes (HR 2.20; 95% CI 1.46 to 3.30) ver-
sus tricyclic antidepressants. Venlafaxine was associated with the
highest risk of seizures.
How the intervention might work
There appears to be a significant relationship between epilepsy and
depression. It is emerging from the studies that they both share
common neurobiological substrates involving hyperactivity of the
hypothalamic pituitary adrenal axis and disturbance of different
neurotransmitter systems, mainly serotonin and norepinephrine
(Dell’osso 2013). The density of serotonin receptors is high in the
mesial temporal and prefrontal areas (Gilliam 2005b). In critical
brain regions, such as the limbic system and prefrontal areas, en-
forced serotonergic circuits seem to be responsible for increasing
seizure threshold (Kondziella 2009).
Antidepressants of the selective serotonin reuptake inhibitor fam-
ily have been reported not only to be safe in treating depression
in patients with epilepsy but to possess antiepileptic properties, as
shown in animal models of epilepsy (Hamid 2013). It has been
suggested based on clinical data that selective serotonin reuptake
inhibitors can decrease the seizure frequency in refractory epilepsy
(Kondziella 2009). This is believed to be due to the increase in the
concentration of serotonin. The study shows that the concentra-
tion of endogenous serotonin (5-HT) and the activity of its recep-
tor subtypes, 5-HT(1A), 5-HT(2C), 5-HT(3) and 5-HT(7), play
a significant role in the pathogenesis of epilepsies (Bagdy 2007).
Medications with serotonin agonist and antagonist properties can
therefore play a significant role in the pathogenesis of epilepsies.
Why it is important to do this review
Depression is common in patients with epilepsy and has a signifi-
cant negative impact on quality of life (Gilliam 2005b; Kondziella
2009). There is concern that patients may not be receiving ap-
propriate treatment for their depression because of uncertainty re-
garding which antidepressant or class works best and the perceived
risk of exacerbating seizures. This review aims to address these is-
sues and inform clinical practice and future research.
O B J E C T I V E S
We aimed to review and synthesise evidence from randomised con-
trolled trials of antidepressants and prospective non-randomised
studies of antidepressants used for treating depression in patients
with epilepsy. The primary objectives were to evaluate the efficacy
and safety of antidepressants in treating depressive symptoms and
the effect on seizure recurrence.
M E T H O D S
Criteria for considering studies for this review
Types of studies
• Randomised controlled trials (RCTs)
• Prospective non-randomised cohort controlled and
uncontrolled studies
◦ Prospective non-randomised cohort studies were
considered in this review because of the known delayed effect of
antidepressants on depressive symptoms which may not be
effectively detected in short-term randomised trials. Similarly,
prospective non-randomised studies are more likely to recruit
populations of patients which better reflect clinical practice since
depression can affect any patient with epilepsy.
Types of participants
We considered participants who satisfied all of the following cri-
teria:
1. any age;
2. diagnosis of epilepsy (any type);
3. treated with antidepressants for co-existing depression
(including patients with major depressive disorder, adjustment
disorder and dysthymic disorder) based on standardised criteria
and/or according to participant scores on validated tools (e.g.
Hamilton Rating Scale for Depression).
Types of interventions
• Intervention group: patients who received an antidepressant
drug in addition to an existing antiepileptic drug regimen.
• Control group(s): patients who received a placebo,
comparative antidepressant, psychotherapy or no treatment in
addition to an existing antiepileptic drug regimen.
Types of outcome measures
Primary outcomes
• Depression scores
◦ The proportion of people with a greater than 50%
improvement in depressive symptoms (defined as a ’response’)
◦ Mean difference in depression scores
If the data allowed, we planned to analyse outcomes at≤ 12 weeks
(short-term), 13 to 26 weeks and≥ 26 weeks (long-term) however
we were unable to perform these analyses.
• Change in seizure frequency
◦ The mean difference in seizure frequency
◦ The proportion of people with a seizure recurrence
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◦ The proportion of people with an episode of status
epilepticus
Secondary outcomes
• Withdrawals
◦ For specific reasons
◦ For any reasons
• Global state
◦ Clinically important change in global state (as defined
by the individual studies)
◦ Relapse (as defined by the individual studies)
• Mental state
◦ Clinically important change in general mental state
score
◦ General mental state score (average and endpoint)
◦ Clinically important change in specific symptoms
(sleep, anhedonia, suicidal ideas)
◦ Specific symptom score (average and endpoint)
• General functioning
◦ Clinically important change in general functioning
◦ General functioning score (average and endpoint)
• Cognitive functioning
◦ Clinically important change in overall cognitive
functioning
◦ Overall cognitive functioning score (endpoint and
average)
◦ Clinically important change in specific cognitive
functioning (attention, concentration, memory, language,
executive functioning)
◦ Specific cognitive score (average and endpoint)
• Quality of life
◦ Clinically important change in quality of life
◦ Any change in quality of life score (average and
endpoint)
• Behaviour
◦ Clinically important change in general behaviour
◦ Any important change in general behaviour (average
and endpoint)
◦ Clinically important change in specific aspects of
behaviour
◦ Any important change in specific aspects of behaviour
score (average and endpoint)
• Adverse effects
◦ Death
◦ Any non-serious general adverse effects
(gastrointestinal effects, anorexia, dizziness, dry mouth,
insomnia, sexual dysfunction, hypotension)
◦ Any serious, specific adverse effects (hypersensitivity
reaction)
◦ Any change in general adverse effect score (average and
endpoint)
◦ Clinically important change in specific adverse effects
◦ Any change in specific adverse effects score (average
and endpoint)
Search methods for identification of studies
Electronic searches
We searched the following databases (search date 31 May 2014):
1. the Cochrane Epilepsy Group Specialised Register;
2. the Cochrane Central Register of Controlled Trials
(CENTRAL 2014, Issue 5) (Appendix 1);
3. MEDLINE (Ovid) (Appendix 2);
4. SCOPUS;
5. PsycINFO; and
6. www.clinicaltrials.gov.
We adapted the MEDLINE search strategy for the SCOPUS and
PsycINFO databases. There were no language restrictions.
Searching other resources
We checked the reference lists of retrieved studies for additional
reports of relevant studies.
We contacted lead authors for any relevant unpublished material.
We identified duplicate studies by screening reports according to
title, authors names, location and medical institute. We omitted
any duplicated studies.
We also identified any grey literature studies published in the last
five years by searching:
1. ZETOC database;
2. ISI Proceedings;
3. International Bureau for Epilepsy (IBE) congress
proceedings database;
4. ILAE congress proceedings database; and
5. abstract books of symposia and congresses, meeting
abstracts and research reports.
Data collection and analysis
Selection of studies
Two authors (MM, JP) independently assessed all citations gen-
erated from the searches for inclusion. A third author (JS) re-in-
spected a random sample of 30% of citations to ensure reliability.
Where disputes arose, we acquired the full report for more detailed
scrutiny.
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Data extraction and management
Two authors (MM, JP) undertook data extraction separately for
each included study. We then cross-checked the data extraction.
We extracted data using pre-standardised data extraction forms.
A third author (JS) re-inspected a random 30% sample to ensure
reliability. We discussed any disagreement, documented decisions
and, if necessary, contacted trialists for clarification.
We extracted the following information from the included studies:
Methodological and trial design
• Year of publication
• Number of study centres
• Language
• Industry funding
• Study design (RCT, prospective cohort study, retrospective
cohort study)
• Blinding
• Type of control group (placebo, comparative
antidepressant, no treatment)
• Sample size
• Follow-up period
• Class of antidepressant as intervention
• Dose range of intervention
• Inclusion and exclusion criteria
Patient demographic information
• Age range
• Number of male/female participants
• Duration of epilepsy
• Previous number of antiepileptic drugs
• Epilepsy type (focal, generalised, unclassified)
• Location of epilepsy (temporal, extra-temporal)
• Baseline mean depression score or severity
• Baseline mean seizure frequency/month
Outcomes
• The number of patients experiencing each outcome
recorded per treatment group
• Number of drop-outs
Assessment of risk of bias in included studies
Two authors (JP, MM) assessed risk of bias in each included study
separately. We cross-checked the ’Risk of bias’ assessment. Due
to the observational design of some of the studies, we utilised a
version of the extended Cochrane Collaboration tool for assessing
risk of bias, currently being developed by the Cochrane Non-Ran-
domised Studies Methods Group. The tool examined selection
bias (sequence generation, allocation concealment), performance
bias (blinding), attrition bias (incomplete outcome data), detec-
tion bias (blinding, other potential threats to validity), report-
ing bias (selective outcome reporting) and the influence of con-
founding variables. We rated the domains of blinding, incomplete
outcome data, selective outcome reporting, confounding variables
and other bias on a five-point scale ranging from low to high risk
of bias according to the risk for the outcome (Appendix 3). The
review authors determined the parameters of this scale (Table 1).
For RCTs, we assessed all domains of the current Cochrane Col-
laboration tool for assessing risk of bias (Higgins 2011).
We made an overall summary judgement of risk of bias for each
study per outcome, followed by an overall judgement per outcome
across studies. We had planned to incorporate the ’Risk of bias’
judgements into the analysis using sensitivity analysis in that a sec-
ondary analysis of the data including only studies rated as low risk
of bias was to be carried out. However; we were unable to do this
due to the small amount of studies and lack of data. We presented
both results in the Results section of the review. Where applica-
ble, we created ’Summary of findings’ tables for outcomes and
graded each outcome accordingly using the Grading of Recom-
mendations Assessment, Development and Evaluation (GRADE)
approach (Guyatt 2008). Outcomes to be reported in summary
of findings tables include:- depression scores, seizure frequency,
withdrawals, general functioning, cognitive functioning, quality
of life and adverse effects as these outcomes are most likely to be
measured and reported.
Measures of treatment effect
For binary outcomes (50% or greater improvement in depressive
symptoms and % treatment withdrawal), we presented results as
risk ratios (RRs) with 95% CIs.
For continuous outcomes (mean change in depression score), we
presented results as mean differences (MDs) or standardised mean
differences (SMDs) with 95% CIs.
Unit of analysis issues
Studies using a variety of depression measures created issues when
combining results in meta-analysis. Where appropriate we used
the SMD to allow for these variances.
Dealing with missing data
We sought missing statistics from studies through contact with the
study authors. We sought reasons for missing data to determine
whether the data were missing at random or not. We found no
data missing at random.
Assessment of heterogeneity
We assessed clinical heterogeneity by comparing the distribution
of important patient factors between studies (age, epilepsy type,
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duration of epilepsy, baseline depression score, baseline seizure fre-
quency) and trial factors (study design, type of control group, an-
tidepressant drug class, type of depression disorder). We assessed
statistical heterogeneity by using the I2 statistic, with an I2 value of
75% or more indicating considerable heterogeneity, 50% to 90%
indicating substantial heterogeneity and 30% to 60% indicating
moderate heterogeneity. If the I2 value was 75% or more, we had
made an a priori decision not to carry out meta-analysis; the review
would then take a narrative form and all comparisons would be
discussed according to the findings presented within the studies.
We planned meta-regression techniques where possible to investi-
gate possible sources of heterogeneity, however we were unable to
investigate this within this review.
Assessment of reporting biases
1. Protocol versus full study
We investigated outcome reporting bias using the ORBIT classi-
fication system, allocating studies a letter from A-I if selective out-
come reporting bias was suspected to be present (Kirkham 2010).
2. Funnel plot
Reporting biases arise when the dissemination of research findings
is influenced by the nature and direction of results (Higgins 2011;
Sterne 2000). Funnel plots can be used in investigating reporting
biases but are of limited power to detect small-study effects. We
did not use funnel plots for outcomes where there were 10 or fewer
studies, or where all studies were of similar sizes.
Data synthesis
We synthesised data using the RR, the MD or the SMD depend-
ing on the measures used in both the controlled and uncontrolled
studies.We carried out a sensitivity analysis to check for differences
between a random-effects model and fixed-effect model in influ-
encing conclusions. If differences between the models existed, we
intended to report outcomes based on the random-effects model,
which incorporates an assumption that the different studies are
estimating different, yet related, intervention effects.
For controlled studies we intended to carry outmeta-analysis using
the Mantel-Haenszel method for dichotomous outcomes and the
inverse variance method for continuous outcomes. For before and
after studies we used the inverse variance methods for continuous
outcomes in meta-analysis.
Wedidnot combine data for outcomes using both randomised and
non-randomised studies.We reported combineddata onoutcomes
for randomised and non-randomised studies separately.
Comparisons we expected to carry out included:
1. intervention group versus controls for change in mean
depression score;
2. intervention group versus controls on % achieving a 50%
improvement in depression scores;
3. intervention group versus controls for change in mean
seizure frequency;
4. intervention versus controls on % of patients withdrawing
from treatment.
We stratified each comparison by type of control group, study de-
sign and/or study characteristics to ensure appropriate combina-
tion of study data.
Subgroup analysis and investigation of heterogeneity
We stratified subgroup analysis by antidepressant drug class,
epilepsy type and age. For investigation of heterogeneity, please
see Assessment of heterogeneity.
Sensitivity analysis
We intended to carry out sensitivity analysis if peculiarities in study
quality were found (Assessment of risk of bias in included studies).
We reported the analysis for all studies and then compared this to
an analysis only of studies at low risk of bias.
R E S U L T S
Description of studies
Results of the search
The searches, outlined above, identified 14 eligible studies. Figure
1 outlines the flow diagram of search results, eligible records and
study exclusions.
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Figure 1. Study flow diagram.
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After exclusions 11 studies remained. Three studies are awaiting
further classification. Two studies met our inclusion criteria but
did not report results for any of the primary or secondary out-
comes (Harmant 1990; Machado 2010). We attempted to con-
tact the authors for any further information on outcomes but we
have not received a response. A further study, identified through
www.clinicaltrials.gov, completed in September 2013 and com-
pared escitalopram versus placebo (Conrad 2013). We attempted
to contact the trial author for further information on outcomes
but received no response.
Included studies
The eight remaining studies met all of the inclusion criteria. Of
these eight reports, we identified three randomised controlled trials
and five non-randomised prospective cohort studies examining
the effect of antidepressant drugs.
We found three randomised trials of antidepressant versus active
control, placebo or no treatment, which reported on the primary
efficacy outcome and which met the inclusion criteria (Li 2005;
Robertson 1985; Zhu 2004). All were single-centre studies. A to-
tal of 173 patients were randomised in these three studies, with
121 patients having partial epilepsy. The remaining five non-ran-
domised prospective cohort studies reported on a total of 298
patients treated with an antidepressant, reported on the primary
efficacy outcome and met the inclusion criteria (Hovorka 2000;
Kanner 2000; Kuhn 2003; Specchio 2004; Thome-Souza 2007).
Two hundred and eighty-two patients had partial epilepsy and
were treated with a selective serotonin reuptake inhibitor.
Hovorka 2000 was a published, single-centre, prospective cohort
study conducted in theCzechRepublic on 43 patients. Two-thirds
of patients had focal epilepsy. Patients were between the ages of
12 and 49 years and 35 patients were female. Inclusion criteria
were defined as patients with a major depressive illness scoring
more than 15 points on the Hamilton Rating Scale for Depression
(HAMD). All patients received citalopram (mean daily dose 22.6
mg+/- 8.3mg) for eightweeks. At four and eight weeks, depression
scores and seizure frequencies were measured and compared to an
unspecified baseline period. There were no treatment withdrawals
and all 43 patients were included in the reported analysis.
Kanner 2000 was a published, single-centre, prospective cohort
study conducted in the USA on 100 patients. Patients were aged
between 6 and 62 years, 95% had focal onset epilepsy and 49 pa-
tients were female. Inclusion criteria were defined as patients with
epilepsy and a depressive illness or obsessive compulsive disorder
(n = 3). All patients received sertraline (25 mg to 200 mg/day;
mean dose of 108 mg +/- 56.9 mg per day) and were followed up
for 0.2 to 38 months. Monthly seizure frequencies were compared
during the treatment period and compared to a 3- and 12- month
retrospective baseline period.No changes in depression scores were
reported. Of the 100 patients, 18 withdrew from the study. All
patients were included in the primary efficacy analysis.
Kuhn 2003 was a published, single-centre, prospective cohort
study conducted in Germany on 75 patients. All had focal onset
epilepsy (temporal lobe). The patients were aged between 19 and
68 years and 45 patients were female. Inclusion criteria were de-
fined as patients having major depression with epilepsy and scor-
ing more than 15 points on the HAMD depression scale. Twenty-
seven patients received mirtazepine (mean daily dose 32.2 mg),
33 patients received citalopram (mean daily dose 24.2 mg) and 15
patients received reboxetine (mean daily dose 6.9 mg). Changes
in depression scores and treatment responders were measured at
four weeks and 20 to 30 weeks, and compared to baseline scores.
Changes in seizure frequency were not measured. Forty-two pa-
tients dropped out; eight dropped out between baseline and week
four, 34 dropped out between week four and weeks 20 to 30. The
last observation carried forward was used and all patients were in-
cluded in the primary efficacy outcomes.
Li 2005 was a published, single-centre, randomised controlled trial
conducted in China on 67 patients. Forty-two patients had gen-
eralised onset epilepsy. The patients were aged between 14 and 62
years and 35 patients were female. Inclusion criteria were defined
as patients having epilepsy defined by the ILAE classification and
depressive illness with a HAMD score of more than 18. Thirty-
three patients were randomised to paroxetine, which was started at
10 mg/day and titrated up to 40 mg/day depending on response.
Thirty-four patients were randomised to doxepin started at 25mg/
day and titrated up according to response (mean 100 mg/day).
The HAMD score was measured at eight weeks and compared
to the baseline score. Seizure frequency was not assessed. Three
patients in the doxepin treatment arm dropped out and were not
included in the primary analysis.
Robertson 1985 was a published, single-centre, randomised,
placebo-controlled trial conducted in the UK on 42 patients. The
majority had focal onset epilepsy. The patients were aged between
18 and 60 years and 26 were female. Inclusion criteria were de-
fined as patients with epilepsy and depression as defined by gen-
eral criteria and a HAMD score of more than 15. Patients were
randomised to amitriptyline, nomifensine or placebo. All treat-
ment arms completed a six-week phase and then both active treat-
ment arms continued the study for a further six weeks. Depression
scores were compared to baseline at 12 weeks of treatment. Three
patients withdrew from the study. Twenty eight patients within
active treatment arms were included in the primary outcome anal-
ysis at 12 weeks.
Specchio 2004 was a published, multi-centre, prospective cohort
study conducted in Italy on 45 patients. Forty-four patients had
focal onset epilepsy. The patients had a mean age of 42.7 years and
31 were female. Inclusion criteria were defined as patients with
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epilepsy on a stable regime of antiepileptic medication and with
a Montgomery-Åsberg Depression Rating Scale (MADRS) score
of 20 or more. All patients received citalopram for four months.
Depression scores and seizure frequency were measured at two and
four months on citalopram and compared to baseline measures.
Six patients withdrew from the study and were omitted from the
primary outcome analysis.
Thome-Souza 2007 was a published, single-centre, prospective
cohort study conducted in Brazil on 36 patients with focal onset
epilepsy. The patients were aged between six and 18 years and
19 were females. Inclusion criteria were defined as patients with
epilepsy and a diagnosis of major depressive disorder as per Kiddie
SADS score. Twenty-eight patients received sertraline (50 mg to
200 mg/day) and eight patients received fluoxetine (20 mg to 80
mg/day) for a duration of 12 to 78 months. Change in depression
scores wasmeasured during the treatment phase and compared to a
six-month baseline period. Seizure exacerbation was also observed
during the treatment phase. One patient dropped out of the study.
All patients were included in the primary outcome analysis.
Zhu 2004 was a published, single-centre, randomised trial of ven-
lafaxine versus no treatment conducted in China on 64 patients.
The patients were aged between 7 and 60 years. Inclusion criteria
were defined as patients with epilepsy (presumed genetic or cause
unknown) and depression. Thirty-two patients were randomised
to venlafaxine 25 mg to 75 mg/day and 32 patients received no
treatment. Depression scores were measured using the HAMD at
eight weeks of treatment and compared to baseline. Seizure fre-
quency as a primary outcome was not reported. There were no
drop-outs and all patients were included in the primary outcome
analysis.
Clinical heterogeneity
Five studies reported outcomes for adults patient only (Hovorka
2000; Kuhn 2003; Li 2005; Robertson 1985; Specchio 2004).
Three studies reported outcomes for adults and children (Kanner
2000; Thome-Souza 2007; Zhu 2004). Six studies included pa-
tients with focal onset epilepsy, whereas two studies included
patients with generalised onset epilepsy (Li 2005; Zhu 2004).
In all trials there was a larger or equal number of female pa-
tients. Six studies evaluated the efficacy of selective serotonin re-
uptake inhibitors (citalopram, sertraline, fluoxetine) versus no
treatment, a tricyclic antidepressant (doxepin), a norepinephrine
reuptake inhibitor (reboxetine) or a-2 antagonists (mirtazapine)
(Hovorka 2000; Kanner 2000; Kuhn 2003; Li 2005; Specchio
2004;Thome-Souza 2007). The remaining two studies evaluated a
serotonin-norepinephrine reuptake inhibitor (venlafaxine) versus
no treatment (Zhu 2004) and a tricyclic antidepressant (amitripty-
line) versus dopamine and a norepinephrine reuptake inhibitor
(nomifensine) (Robertson 1985). Five studies used the Hamilton
Rating Scale for depression (Hovorka 2000; Kuhn 2003; Li 2005;
Robertson 1985; Zhu 2004). One study used the Montgomery-
Åsberg Depression Rating Scale (MADRS) (Specchio 2004), one
study used the Kiddie SADS depression score (Thome-Souza
2007), and one study did not report the use of a specific depression
rating scale (Kanner 2000).
Excluded studies
We excluded three studies. Two studies identified through
www.clinicaltrials.gov were clinical trials comparing cognitive be-
havioural therapy versus sertraline and escitalopram versus no
treatment, respectively (Gilliam 2005a; Kocsis 2007). Both trials
were terminated early due to problems with recruitment. There
were no available published data for either trial and we excluded
both. The third study reported on a small case series of patients
with epilepsy taking a combined tricyclic antidepressant and SSRI
for depression and did not fulfil the inclusion criteria (Blumer
1997). See Characteristics of excluded studies for more details of
the studies.
Risk of bias in included studies
We rated risk of bias across each domain for each study and then
made an overall risk of bias judgement for each study. Overall,
we rated four studies as high risk of bias (Hovorka 2000; Kanner
2000; Kuhn 2003; Thome-Souza 2007), and we rated four as
unclear risk of bias (Li 2005; Robertson 1985; Specchio 2004; Zhu
2004). See Figure 2 for a ’Risk of bias’ summary (review authors’
judgements about each risk of bias item for each included study).
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Figure 2. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
We rated two RCTs as low risk of bias for sequence generation
as they used adequate methods (Li 2005; Robertson 1985). For
allocation concealment we rated Li 2005 as unclear and we rated
Robertson 1985 as low risk of bias. We rated the other RCT as
unclear risk of bias for both sequence generation and allocation
concealment (Zhu 2004). (See the ’Risk of bias’ tables for more
detailed information on methodology).
The prospective cohort studies were non-randomised studies
(Hovorka 2000; Kanner 2000; Kuhn 2003; Specchio 2004;
Thome-Souza 2007), and therefore we rated them as high risk of
bias for these two domains.
Blinding
For the RCTs, we rated two as low risk of bias as study person-
nel, participants and outcome assessors were blinded (Li 2005;
Robertson 1985). There were no clear methods of blinding re-
ported for the third RCT, therefore we rated this study as unclear
risk of bias (Zhu 2004).
For the prospective cohort studies, there was either no reported
blinding of participants or outcome assessors (Hovorka 2000;
Kanner 2000; Thome-Souza 2007), therefore we rated these stud-
ies as high risk of bias. For two other non-randomised studies
blinding was reported but the methods were unclear and so we
rated them as unclear risk of bias (Kuhn 2003; Specchio 2004).
Incomplete outcome data
For the RCTs, two reported missing data and did not perform
an intention-to-treat analysis, but they did report both numerator
and denominator data (Li 2005; Robertson 1985). We rated these
as unclear risk of bias. The third RCT did not report any missing
data and an intention-to-treat analysis was carried out, therefore
we rated this study as low risk of bias (Zhu 2004). (See the ’Risk
of bias’ tables for more detailed information on methodology).
For the prospective cohort studies, we rated four as low risk of
bias as they either had no missing data or carried out an intention-
to-treat analysis (Hovorka 2000; Kanner 2000; Specchio 2004;
Thome-Souza 2007). The fifth study reported missing data with
18 patients lost to follow-up and used the last observation carried
forward approach in analysis; we therefore rated this study as un-
clear risk of bias (Kuhn 2003).
Selective reporting
We rated all studies except for one RCT (Li 2005) as low risk of
bias as they reported outcomes that were clearly stated in their
methods section. For the study by Li 2005, adverse event outcomes
were not reported but were stated as an outcome in their methods
section, therefore we rated this study as high risk of bias and this
studywas allocated the letter E on theORBIT classification system
as it is clear that this outcome was measured but not necessarily
analysed.
Other potential sources of bias
One prospective cohort study used an insufficient measure of de-
pression, by looking for “complete resolution of identified target
psychiatric symptoms” as a measure of response to treatment; we
therefore rated it as high risk of bias (Kanner 2000).
For theRCTs it was unclear whether there were any other potential
sources of bias and so we rated all the RCTs as unclear risk of
bias for this domain. We rated the other non-randomised studies
as low risk of bias (Hovorka 2000; Kuhn 2003; Specchio 2004;
Thome-Souza 2007).
Confounding variables
Risk of bias for confounding variables was only assessed in non-
randomised studies. All were rated as high risk of bias as no study
considered the importance of confounding factors or adjusted for
them appropriately within the analyses.
Effects of interventions
See: Summary of findings for the main comparison Paroxetine
compared to doxepin for people with epilepsy and depression;
Summary of findings 2 Amitriptyline compared to nomifensine
for people with epilepsy and depression; Summary of findings
3 Venlafaxine compared to no treatment for people with epilepsy
and depression; Summary of findings 4 Citalopram (before and
after) for people with epilepsy and depression
Primary outcomes
(1) Depression scores: proportion with a greater than 50%
improvement
All randomised controlled trials (RCTs) reported on the propor-
tion with a 50% or more improvement in depression scores. The
RCTs analysed different treatment comparisons and we were un-
able to combine the data in meta-analysis.
Li 2005 compared paroxetine (20 mg to 40 mg/day) versus dox-
epin (mean dose 100 mg/day), including a total of 67 patients.
The numbers of responders were 27/33 (82%) in the paroxetine
group and 24/34 (71%) in the doxepin group. The risk ratio for
the proportion with a 50% of more improvement in depression
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scores for paroxetine versus doxepin was 1.16 (95% confidence
interval (CI) 0.88 to 1.52; P value > 0.05) (Analysis 1.1).
Robertson 1985 compared amitriptyline (75 mg/day) versus
nomifensine (75 mg/day) versus placebo, including a total of 42
patients. The number of responders was reported at 12 weeks for
active treatment groups. The number of responders for all treat-
ment groups at six weeks is not reported. The numbers of respon-
ders at 12 weeks were 6/14 (43%) in the amitriptyline group and
11/14 (79%) in the nomifensine group. The risk ratio for the pro-
portion with a 50% or more improvement in depression scores for
amitriptyline versus nomifensine was 0.55 (95% CI 0.28 to 1.06;
P value > 0.05)( Analysis 2.1).
Zhu 2004 compared venlafaxine (25 mg to 75 mg/day) versus no
treatment and included 64 patients. The numbers of responders
were 22/32 (69%) in the venlafaxine group and 6/32 (19%) in
the no treatment group. The risk ratio for the proportion with a
50% or more improvement in depression scores for venlafaxine
versus no treatment was 3.25 (95% CI 1.19 to 8.90; P value <
0.05) (Analysis 3.1).
Four of five prospective cohort studies reported on the proportion
with a 50% or more improvement in depression scores. The fifth
study did not use a validated depression scale (Kanner 2000).
Hovorka 2000 observed 28/43 (65%) patients with a 50% or
more improvement in depression scores following eight weeks of
treatment with citalopram (mean dose 23 mg/day).
Kuhn 2003 observed 17/27 patients (52%) in the mirtazepine
group (mean dose 32 mg/day), 12/33 patients (36%) in the citalo-
pram group (mean dose 24 mg/day) and 8/15 patients (53%) in
the reboxetine group (mean dose 7 mg/day) with a 50% or more
improvement in depression scores following 20 to 30 weeks of
treatment. There was no statistical difference between the treat-
ment groups.
Specchio 2004 observed 11/45 patients (24%) with a 50% or
more improvement in depression scores following four months of
treatment with citalopram (20 mg/day).
Thome-Souza 2007 observed 35/36 patients (97%) with a 50%
or more improvement in depression scores following one year of
treatment with sertraline (mean dose 111 mg/day) or fluoxetine
(mean 46 mg/day).
(2) Depression scores: mean difference
Two of three RCTS reported on the mean difference in depression
scores using the Hamilton Rating Scale for Depression (HAMD)
depression scale (Li 2005; Zhu 2004). The RCTs compared dif-
ferent treatment groups and we were unable to combine the data
in any meta-analysis.
Li 2005 compared paroxetine (20 mg to 40 mg/day) and doxepin
(mean dose 100 mg/day), including a total of 67 patients. The
effect estimate for the mean difference in depression scores for
paroxetine versus doxepin was 0.65 (95% CI -2.15 to 3.45) (
Analysis 1.2). There was no significant difference between the
treatment groups.
Zhu 2004 compared venlafaxine (25 mg to 75 mg/day) versus
no treatment and included 64 patients. The effect estimate for
the mean difference in depression scores for venlafaxine versus no
treatment was -7.59 (95% CI -11.52 to -3.66) (Analysis 3.2 ).
There was a statistically significant difference between treatment
groups.
Three of five prospective cohort studies reported on the mean dif-
ference in depression scores (Hovorka 2000; Kuhn 2003; Specchio
2004).
We were able to perform meta-analysis, pooling data across two
uncontrolled studies of citalopram including a total of 88 patients
(Hovorka 2000; Specchio 2004). The average doses of citalopram
were 22 mg/day and 20 mg/day respectively. The effect estimate
for the standardised mean difference (SMD) in depression scores
before and after was large, with an estimate of 1.17 (95% CI
0.96 to 1.38) (Analysis 4.1). The I2 statistic for heterogeneity
was 53%, which may reflect differences between the two studies
in the treatment period. One study reported outcomes following
four months of treatment (Specchio 2004), versus two months of
treatment in the other study (Hovorka 2000). Due to the level of
statistical heterogeneity we performed a random-effects analysis,
which showed no change in significance (SMD1.17; 95%CI 0.86
to 1.47).
The remaining study reported mean depression scores before
and after treatment with mirtazepine, citalopram and reboxetine
(Kuhn 2003). Baseline mean depression scores on the HAMD
depression scale were 23, 22.5 and 23 respectively. Following 20
to 30 weeks of treatment the mean depression scores decreased to
13.5, 14 and 13.5 respectively. There were no significant differ-
ences according to treatment group.
(3) Seizure frequency: mean difference
None of the RCTs reported on mean difference in seizure fre-
quency between baseline and end of treatment period. One RCT
reported no increase in seizure frequency in both treatment groups
(Li 2005).
Three of five prospective studies reported on changes in mean
seizure frequency between baseline and treatment periods (
Hovorka 2000; Kanner 2000; Specchio 2004).
We were able to perform meta-analysis, pooling data across two
uncontrolled studies of citalopram including a total of 88 patients
(Hovorka 2000; Specchio 2004) (Analysis 4.2).The I2 statistic for
heterogeneity in the effect estimate for the standardised mean dif-
ference in seizure frequency was 81%. We have therefore not re-
ported the effect estimate. Possible reasons for a high I2 statistic
value include differences in mean baseline seizure frequency, treat-
ment duration and mean age of patients.
Kanner 2000 reported no statistically significant difference in
seizure frequency at baseline versus treatment period for the 100
patients treated with sertraline (mean dose 108 mg/day).
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(4) Seizure frequency: seizure recurrence or episode of
status epilepticus
Only one study reported on one patient with a seizure recurrence
(Specchio 2004). There were no reported episodes of status epilep-
ticus reported in any of the eight studies.
Secondary outcomes
(1) Withdrawals: for any reason
Of the RCTs, two reported clearly the number of patients with-
drawing for any reason (Li 2005; Robertson 1985).
Li 2005 reported 3/34 patients (9%) withdrawing from the dox-
epin treatment group versus 0/33 patients from the paroxetine
group. The risk ratio for treatment withdrawal for paroxetine ver-
sus doxepin was 0.15 (95% CI 0.01 to 2.74; P value = 0.20)
(Analysis 1.3). The specific reasons for withdrawal were not re-
ported.
Robertson 1985 reported 1/14 patients (7%) withdrawing from
the amitriptyline group, 1/14 from the nomifensine group and
1/14 from the placebo group. The patient withdrew from the
nomifensine group because of increased seizures.
All five prospective studies reported on the number of patients
withdrawing from the study.
Hovorka 2000 reported no treatment withdrawals from the study.
Kanner 2000 reported 18/100 patients (18%) treated with ser-
traline withdrawing from the study. All withdrew due to adverse
events.
Kuhn 2003 reported 20/27 patients (74%) in the mirtazepine
group, 16/33 patients (48%) in the citalopram group and 6/15
patients (40%) in the reboxetine group withdrawing from the
study after 20 to 30 weeks of treatment. Adverse events accounted
for 8/20 withdrawing from the mirtazepine group, 6/16 from the
citalopram group and 3/6 from the reboxetine group. Only three
patients (two mirtazepine and one citalopram) withdrew due to
inefficacy. The remaining 22 patients were lost to follow-up.
Specchio 2004 reported 6/45 patients (13%) treated with citalo-
pram withdrawing from the study. Four withdrew because of ad-
verse events, one due to poor compliance and one due to concur-
rent illness.
Thome-Souza 2007 reported 1/36 patients treated with a selec-
tive serotonin reuptake inhibitor (SSRI) (sertraline) withdrawing
because of exacerbation of seizures.
(2) Global State
None of the included studies reported on global state outcomes
(3) Mental State
None of the included studies reported on mental state outcomes
(4) General Functioning
None of the included studies reported on general functioning out-
comes
(5) Cognitive Functioning
None of the included studies reported on cognitive functioning
outcomes
(6) Quality of life
None of the included studies reported on quality of life outcomes
(7) Behaviour
None of the included studies reported on behaviour outcomes
(8) Adverse effects
Of the RCTs, one reported clearly the number of patients expe-
riencing specific side effects in the treatment groups (Li 2005).
Comparing paroxetine versus doxepin, the risk ratio for blurred
vision was 0.34 (95% CI 0.09 to 1.32,), dizziness 0.21 (95% CI
0.03 to 1.37), dry mouth 0.26 (95% CI 0.06 to 1.20), sleep disor-
ders 0.32 (95% CI 0.08 to 1.20) and urinary retention 0.34 (95%
CI 0.01 to 21.99) (see Analysis 1.4). There were no significant
differences between treatment groups.
All five prospective cohort studies reported on adverse events. The
studies analysed different treatment comparisons and we were un-
able to combine the data in meta-analysis.
Hovorka 2000 reported 3/43 patients (7%) experiencing nausea
and 2/43 patients (5%) experiencing sexual dysfunction following
eight weeks of treatment with citalopram.
Kanner 2000 reported 9/100 patients (9%) experiencing sedation,
7/100 patients (7%) experiencing hypomanic symptoms, 1/100
patients (1%) experiencing rheumatic pain and 1/100 patients
(1%) experiencing myoclonus following an average 10-month du-
ration of treatment with sertraline.
Kuhn 2003 reported 13/75 patients experiencing side effects;
weight gain (5/75), sedation (2/75) and sexual dysfunction (2/75)
were the most common side effects.
Specchio 2004 reported 22/45 patients (56%) experiencing side
effects; headache (15%), nausea (11%), dizziness (9%), drowsiness
(7%) and fatigue (7%) were the most common side effects.
Thome-Souza 2007 reported 1/36 patients (3%) experiencing fa-
cial rash and 1/36 patients (3%) experiencing gastrointestinal dis-
order.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Amitriptyline compared to nomifensine for people with epilepsy and depression
Patient or population: people with epilepsy and depression
Settings: outpatients
Intervention: amitriptyline
Comparison: nomifensine
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Nomifensine Amitriptyline
> 50% reduction in de-
pressive symptoms
786 per 1000 432 per 1000
(220 to 833)
RR 0.55
(0.28 to 1.06)
28
(1 study)
⊕⊕⊕©1
moderate
1 study com-
pared amitriptyline and
nomifensine in reducing
seizures and there was
no significant difference
found between the 2
groups
Seizure frequency - - - 0
(0 studies)
- No data contributed to
this outcome
Withdrawals - - - 0
(0 studies)
- No data contributed to
this outcome
Cognitive functioning - - - 0
(0 studies)
- No data contributed to
this outcome
Quality of life - - - 0
(0 studies)
- No data contributed to
this outcome
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Adverse effects - - - 0
(0 studies)
- No data contributed to
this outcome
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1Quality downgraded for imprecision due to only one study contributing to the outcomes and it was a small study.
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Venlafaxine compared to no treatment for people with epilepsy and depression
Patient or population: people with epilepsy and depression
Settings: outpatients
Intervention: venlafaxine
Comparison: no treatment
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
No treatment Venlafaxine
> 50% reduction in de-
pressive symptoms
125 per 1000 406 per 1000
(149 to 1000)
RR 3.25
(1.19 to 8.9)
64
(1 study)
⊕⊕⊕©1
moderate
1 study compared ven-
lafaxine to a no treatment
control group and found
that venlafaxinewasmore
than 3 times more effec-
tive in reducing seizures
compared to controls
Mean depression scores
- HAMD
The mean HAMD depres-
sion score in the interven-
tion groups was
7.59 lower
(-11.52 to -3.66 lower)
64
(1 study)
⊕⊕⊕©1
moderate
The same study found
mean depression scores
to be significantly lower
in the venlafaxine group
compared to the control
group
Seizure frequency - - - 0
(0 studies)
- No data contributed to
this outcome
Withdrawals - - - 0
(0 studies)
- No data contributed to
this outcome
Cognitive functioning - - - 0
(0 studies)
- No data contributed to
this outcome20
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Quality of life - - - 0
(0 studies)
- No data contributed to
this outcome
Adverse effects - - - 0
(0 studies)
- No data contributed to
this outcome
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; HAMD: Hamilton Rating Scale for Depression; RR: risk ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1Quality downgraded for imprecision due to only one study contributing to the outcomes and it was a small study.
2
1
A
n
tid
e
p
re
ssa
n
ts
fo
r
p
e
o
p
le
w
ith
e
p
ile
p
sy
a
n
d
d
e
p
re
ssio
n
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
4
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
Citalopram (before and after) for people with epilepsy and depression
Patient or population: people with epilepsy and depression
Settings: outpatients
Intervention: citalopram (before and after)
Outcomes Illustrative comparative
risks* (95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Corresponding risk
Citalopram (before and
after)
Mean depression scores
- HAMD
The mean HAMD depres-
sion score in the interven-
tion groups was
1.17 higher
(0.96 to 1.38 higher)
88
(2 studies)
⊕⊕©©
low1,2
2 before and after stud-
ies investigated citalo-
pram and found that de-
pression scores were sig-
nificantly lower after treat-
ment
Mean monthly seizure
frequency
88
(2 studies)
⊕©©©
very low1,3
2 studies found mixed ev-
idence for the effect of
citalopram on seizure fre-
quency. Due to high het-
erogeneity the overall ef-
fect estimate is not pre-
sented
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk
(and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: confidence interval; HAMD: Hamilton Rating Scale for Depression
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change
the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to
change the estimate.
Very low quality: We are very uncertain about the estimate.
1Across the studies there were concerns about bias with regards to the methods of blinding and methods to deal with confounding
variables.
2Large effect found.
3Statistical heterogeneity was significant (P = 0.02; I² = 81%).
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D I S C U S S I O N
Summary of main results
Depression is the most common psychiatric comorbidity in
epilepsy and is associated with poor quality of life (Fiest 2013;
Taylor 2011). Depression is also a risk factor for refractory epilepsy
(Anhoury 2000; Hitiris 2007), suggesting a bidirectional relation-
ship between the two conditions. This may reflect shared patho-
physiology, for example changes in serotonin neurotransmission,
hyperactivity of the hypothalamic pituitary adrenal axis and im-
balances between the excitatory and inhibitory neurotransmitters
glutamate andGABA respectively (Kanner 2011). The association
may also reflect iatrogenic interplay between antiepileptic drugs
and antidepressants used to treat depression and epilepsy.
In this review we synthesised the available data from randomised
trials and non-randomised prospective studies of antidepressants
used to treat depression in patients with epilepsy. We specifically
sought to examine the effect of antidepressants ondepressive symp-
toms and any potential risk of worsening seizures. We included
non-randomised studies because of the delayed effect of antide-
pressants on depressive symptoms and to better reflect effective-
ness in populations seen in clinical practice. However, including
non-randomised studies within this review may have exposed to
selection biases, including publication bias which could lead to
unreliable and often inflated estimates of effect (Maguire 2008).
Similarly confounding may occur where allocation to treatment is
influenced by unmeasured factors which cannot be accounted for
within a analysis, for example comorbidities or level of education.
The review identified no large, well-conducted randomised con-
trolled trials (RCTs) of antidepressant treatment used in epilepsy
patients, and our review included three small RCTs. There were no
published trials comparing antidepressant treatment versus psy-
chotherapy in patients with epilepsy. The RCTs showed that ven-
lafaxine significantly improved depressive symptoms when com-
pared to no treatment, and that there was no difference between
amitriptyline and nomifensine in improving depressive symptoms.
The RCTs did not allow meaningful comparisons among the dif-
ferent classes of antidepressants. We therefore do not know which
antidepressant or class of antidepressant is most effective. None of
theRCTs reported seizure frequency changes during the trial.Only
one RCT reported information on adverse events. We therefore
have no randomised data to reliably inform on the likely impact of
antidepressants on seizure control. We have limited information
on adverse events encountered in clinical trials.
The five prospective cohort studies were of low quality, examining
small numbers of patients treated predominantly with SSRIs. The
combined meta-analysis of two studies examining citalopram at
20 mg/day showed evidence of an effect on depressive symptoms.
We could not combine the data on seizure frequency changes due
to marked heterogeneity. However in the three studies reporting
seizure frequency changes, none detected a significant increase in
seizures. Only one study reported on one patient with a seizure
recurrence on antidepressant treatment (citalopram). Whilst the
data are of low quality in terms of impact on seizures, there is
broad agreement across the prospective cohort studies of limited or
no impact on seizures with selective serotonin reuptake inhibitors
(SSRIs).
Patients withdrawing from antidepressants were more likely to do
so because of adverse events rather than lack of efficacy. Reported
adverse events for SSRIs included nausea, dizziness, sedation, gas-
trointestinal disturbance and sexual dysfunction. We have no re-
liable information on the comparative risk of adverse events with
different classes of antidepressant treatment.
This review has ascertained that there is very limited evidence of
an effect of antidepressants on depressive symptoms in patients
with epilepsy. We do not have any reliable high-quality evidence
to inform on treatment effect or the best choice of antidepressant
drug or class of drug for treating depression with the lowest risk of
seizure exacerbation. We do not have any evidence on how antide-
pressants compare with psychotherapy in patients with epilepsy
and depression.
Quality of the evidence
Overall, we rated four prospective cohort studies as high risk of bias
(Hovorka 2000; Kanner 2000; Kuhn 2003; Thome-Souza 2007),
and four studies (all RCTs and one prospective cohort study) as
unclear risk of bias (Li 2005; Robertson 1985; Specchio 2004;
Zhu 2004). The ’Summary of findings’ tables for each compari-
son examined shows that the quality of the evidence ranged from
moderate quality to low quality. Where data were combined in
meta-analysis we rated the quality of evidence as low.
Potential biases in the review process
One potential bias in the review process concerns the extended risk
of bias tool for non-randomised studies. The tool is designed for
the purpose of primarily assessing cohort-like studies which have
control groups. In our study we identified three studies whichwere
uncontrolled and used this risk of bias tool to assess them for risk of
bias and this may have brought bias into the review process. There
is currently a lack of quality assessment tools which are deemed
appropriate for these types of observational studies therefore we
took the decision to use the same tool across all included studies.
With respect to the same tool, the parameters for assessing risk of
bias across all domains except sequence generation and allocation
concealment were review author defined and therefore specific
to this review only. Although this was part of how the tool was
designed to be used, this may have introduced bias into the review
process.
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A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Existing evidence on the effectiveness of antidepressants in treat-
ing depressive symptoms associated with epilepsy is very limited.
Only one small randomised controlled trial (RCT) demonstrated
a statistically significant effect of venlafaxine on depressive symp-
toms, although the study had unclear bias and did not address
the impact of seizure control on outcomes. The remaining analy-
ses did not demonstrate a statistically significant effect on depres-
sive symptoms, although the estimates are in the direction of a
treatment effect. We have no high quality evidence to inform the
choice of antidepressant drug or class of drug for treating depres-
sion in people with epilepsy. Two expert consensus statements rec-
ommend selective serotonin reuptake inhibitors (SSRIs) as first-
line treatment, given better safety and tolerability (Barry 2008;
Kerr 2011). This review provides low-quality evidence of safety in
terms of seizure exacerbation with SSRIs, but there are no available
comparative data on antidepressant classes and safety in relation
to seizures. There are currently no comparative data on antide-
pressants and psychotherapy for treating depression in epilepsy,
although psychotherapy could be considered in patients unwill-
ing to take antidepressants or where there are unacceptable side
effects.
Implications for research
Randomised controlled trials of antidepressants and psychother-
apy in large cohorts of patients with epilepsy and depression are
needed to better inform treatment policy in the future. Quality of
life outcomes would be an additional useful measure in evaluating
treatment effect.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Hovorka 2000
Methods A single-centre, non-randomised, uncontrolled, prospective before and after study
(Prague)
Baseline period: 2 months
Treatment period: 8 weeks
Participants 43 people with focal epilepsy exceeding 15 points on the HAMD-21 scale for depression
35 females and 8 males
Aged 21 to 49 years: mean 33.2 years
Interventions Citalopram at a flexible dose; the average dose was 19.3 mg +/- 2.6 mg at the end of the
first month, 22.62 mg +/- 8.3 mg at the end of the second month
Outcomes 1) Seizure frequency
2) Depressive symptoms measured by the HAMD-21
3) Adverse effects
Notes No drop-outs and no exclusions from the analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk No randomisation methods used
Allocation concealment (selection bias) High risk Nomethods for concealing allocation used
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No methods of blinding used. Rated 5 on
scale for risk of bias
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Outcome assessor not blinded. Rated 5 on
scale for risk of bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing data. Rated 1 on scale for risk
of bias
Selective reporting (reporting bias) Low risk Outcomes stated in methods section of re-
port are present in the results. No protocol
available. Rated 2 on scale for risk of bias
Other bias Low risk No other risk of bias detected. Rated 1 on
scale for risk of bias
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Hovorka 2000 (Continued)
Confounding variables High risk No confounding variables considered or
adjusted for. Rated 5 on scale for risk of
bias
Kanner 2000
Methods A single-centre, non-randomised, uncontrolled, prospective before and after study (US)
Baseline period: Not reported
Treatment period: Mean 10.3 months (0.2-38 months)
Participants 100 people with focal epilepsy, with depressive or obsessive compulsive disorder
51 males and 49 females
Aged 6 to 62 years: mean 29.9 years
Interventions Sertraline, mean dose of 108 mg +/- 56.9 mg per day
Outcomes 1) Improvement in depressive symptoms
2) Seizure frequency
3) Adverse effects
Notes 18 people withdrew due to adverse effects; all included in analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk No randomisation methods used
Allocation concealment (selection bias) High risk Nomethods for concealing allocation used
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No methods of blinding used. Rated 5 on
scale for risk of bias
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Outcome assessor not blinded. Rated 5 on
scale for risk of bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing data and intention-to-treat
analysis carried out. Rated 1 on scale for
risk of bias
Selective reporting (reporting bias) Low risk Outcomes stated in methods section of re-
port are present in the results. No protocol
available. Rated 2 on scale for risk of bias
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Kanner 2000 (Continued)
Other bias High risk Measure of depression not an accurate or
reliable measure. Rated 4 on scale of risk of
bias
Confounding variables High risk No confounding variables considered or
adjusted for. Rated 5 on scale for risk of
bias
Kuhn 2003
Methods A single-centre, non-randomised, prospective study (Germany)
Baseline period: 4 days
Observation period: 20 to 30 weeks
Participants 75 people with temporal lobe epilepsy exceeding 15 points on the HAMD-21 scale for
depression
45 females and 30 males
Aged 19 to 68 years: mean 40.1 years
Interventions Citalopram (n = 33), dose at endpoint: 24.2 mg
Mirtazapine (n = 27), dose at endpoint: 32.2 mg
Reboxetine (n = 15), dose at endpoint: 6.9 mg
Outcomes 1) Improvement in depressive symptoms
2) Seizure frequency and severity
3) Adverse effects
Notes Large amount of withdrawals from week 4 to weeks 20 to 30. Last observation carried
forward approach used
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk No randomisation methods used
Allocation concealment (selection bias) High risk Nomethods for concealing allocation used
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Some study personnel blinded; participants
not blinded. Rated 3 on scale for risk of
bias
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear whether outcome assessor blinded.
Rated 3 on scale for risk of bias
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Kuhn 2003 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Missing data detected; last observation car-
ried forward approach employed. Rated 3
on scale for risk of bias
Selective reporting (reporting bias) Low risk Outcomes stated in methods section of re-
port are present in the results. No protocol
available. Rated 2 on scale for risk of bias
Other bias Low risk No other risk of bias detected. Rated 1 on
scale for risk of bias
Confounding variables High risk No confounding variables considered or
adjusted for. Rated 5 on scale for risk of
bias
Li 2005
Methods A single-centre, randomised controlled trial (China)
Baseline period: unclear
Treatment phase: 8 weeks
Participants 67 patients with epilepsy and depression (meeting CCMD-3 criteria for depression and
HAMD-21 score >18)
Interventions Paroxetine (n = 33): 17 males, 16 females aged 14 to 62 years 10 mg to 40 mg/day
Doxepin (n = 34): 15 males, 19 females, aged 16 to 59 years, dose 25 mg/day titrated
up according to response (mean dose 100 mg)
Outcomes 1) Change in depression scores (HAMD-21) from baseline
2) Adverse events
Notes 3 patients discontinued study in doxepin arm because of adverse events, with 31 patients
analysed for this treatment arm
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation carried out by flipping of a
coin
Allocation concealment (selection bias) Unclear risk No details available regarding methods of
allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Patients blinded
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Li 2005 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessor blinded
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Missing data reported, ITT not employed
Selective reporting (reporting bias) High risk Adverse events not reported in results.
Rated as letter E in ORBIT tool
Other bias Unclear risk Insufficient details in report to judge the
influence of other bias
Confounding variables Low risk NA
Robertson 1985
Methods A single-centre, randomised, double-blind, controlled trial (UK)
Baseline period: unclear
Treatment period: 12 weeks (6 weeks for all 3 arms of trial, then 6 weeks for the 2
antidepressants only)
Participants 42 people with epilepsy exceeding 15 points on the HAMD-21 scale for depression
26 females and 13 males
Aged 18 to 60 years
Interventions Amitriptyline (n = 14) 25mg TDS
Nomifensine (n = 14) 25mg TDS
Placebo (n = 14)
Outcomes 1) Improvement in depressive symptoms
2) Seizure frequency
3) Adverse effects
Notes 39 people included in the analysis. At 6 weeks non-responders in the active drug arms
had dose doubled and those in the placebo arm were withdrawn from the study
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomnumber codes employed, however
generation of this randomisation sequence
is unclear
Allocation concealment (selection bias) Low risk Pharmacy-controlled allocation
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Robertson 1985 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Study personnel and participants blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessor blinded
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Missing data detected and attrition re-
ported
Selective reporting (reporting bias) Low risk Outcomes stated in methods section of re-
port are present in the results. No protocol
available
Other bias Unclear risk After 6weeks, placebo group removed from
trial; only active antidepressant treatment
groups continued in the trial
Confounding variables Low risk NA
Specchio 2004
Methods Amulti-centre, non-randomised, uncontrolled, prospective before and after study (Italy)
Baseline period: Not reported
Treatment period: 4 months
Participants 45 people with focal epilepsy and exceeding or equal to 20 on the MADRS
31 females and 14 males
Mean age of 42.7 years
Interventions Citalopram 20 mg per day
Outcomes 1) Seizure frequency
2) Improvement in depression measured by MADRS and Zung-SDS
3) Adverse effects
Notes 39 people received intended treatment and analysed
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk No randomisation methods used
Allocation concealment (selection bias) High risk Nomethods for concealing allocation used
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Specchio 2004 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No details given regarding methods of
blinding. Rated 3 on scale for risk of bias
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No details given regarding methods of
blinding. Rated 3 on scale for risk of bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk Small amount of missing data reported.
Intention-to treat-analysis not employed.
Rated 2 on scale for risk of bias
Selective reporting (reporting bias) Low risk Outcomes stated in methods section of re-
port are present in the results. No protocol
available. Rated 2 on scale for risk of bias
Other bias Low risk No other risk of bias detected. Rated 1 on
scale for risk of bias
Confounding variables High risk No confounding variables considered or
adjusted for. Rated 5 on scale for risk of
bias
Thome-Souza 2007
Methods A single-centre, non-randomised, uncontrolled, prospective before and after study
(Brazil)
Baseline period: Not reported
Treatment period: Mean 25.8 months (range 12-78)
Participants 36 children and adolescents with focal epilepsy and diagnosis of depression
19 females and 17 males
Aged 5 to 18 years, mean: 12.7 years
Interventions Sertraline up to 200 mg per day, mean dose 111.5 mg per day (50 to 200 mg)
Fluoxetine up to 80 mg per day, mean dose 45.7 mg per day (20 to 80 mg)
Outcomes 1) Seizure severity
2) Improvement in depressive symptoms
3) Adverse effects
Notes No drop-outs
Risk of bias
Bias Authors’ judgement Support for judgement
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Thome-Souza 2007 (Continued)
Random sequence generation (selection
bias)
High risk No randomisation methods used
Allocation concealment (selection bias) High risk Nomethods for concealing allocation used
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants not blinded; unclear about
other study personnel. Rated 4 on scale for
risk of bias
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear whether outcome assessors blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing data
Selective reporting (reporting bias) Low risk Outcomes stated in methods section of re-
port are present in the results. No protocol
available. Rated 2 on scale for risk of bias
Other bias Low risk No other risk of bias detected. Rated 1 on
scale for risk of bias
Confounding variables High risk Some confounding variables considered
but not adjusted for in the analysis. Rated
4 on scale for risk of bias
Zhu 2004
Methods Single-centre, randomised trial of venlafaxine versus no treatment (China)
Baseline period: Not reported
Treatment period: 8 weeks
Participants 64 people with epilepsy (presumed genetic or cause unknown) and depression
39 males and 25 females
Aged 7 to 60 years (mean 27 years)
Interventions Venlafaxine 25 mg to 75 mg/day (n = 32)
No treatment (n = 32)
Outcomes 1) Change in HAMD-21 scores
2) Adverse events
Notes No drop-outs
Risk of bias
Bias Authors’ judgement Support for judgement
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Zhu 2004 (Continued)
Random sequence generation (selection
bias)
Unclear risk Methods for generation of random se-
quence are not detailed in the report
Allocation concealment (selection bias) Unclear risk Methods for allocation are not detailed in
the report
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No details of blinding methods in the re-
port
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear whether outcome assessor blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing data
Selective reporting (reporting bias) Low risk Outcomes stated in methods section of re-
port are present in the results. No protocol
available
Other bias Unclear risk Insufficient details in report to judge the
influence of other bias
Confounding variables Low risk NA
CCMD-3: Chinese Classification of Mental Disorders
HAMD: Hamilton Rating Scale for Depression
ITT: Intention-To-Treat
MADRS: Montgomery-Åsberg Depression Rating Scale
NA: Not Applicable
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Blumer 1997 Case series study not meeting the inclusion criteria
Gilliam 2005a Trial listed on www.clinicaltrials.gov and recorded as terminated
Kocsis 2007 Trial listed on www.clinicaltrials.gov and recorded as terminated
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Characteristics of studies awaiting assessment [ordered by study ID]
Conrad 2013
Methods A double-blind, placebo-controlled, randomised trial
Participants Adults with temporal lobe epilepsy and meeting DSM-IV criteria for depression with a MADRS score greater than
or equal to 15
Interventions Escitalopram versus placebo
Outcomes 1) Change in depressive and anxiety symptoms
2) Seizure frequency
3) Quality of life
Notes Trial listed on www.clinicaltrials.gov and recorded as complete. We attempted to contact the lead trialist but received
no response
Harmant 1990
Methods Prospective cohort study
Participants 35 patients with epilepsy and depression
Interventions Fluvoxamine 50 to 200 mg (mean 125 mg)
Outcomes Seizure frequency
Notes No available contact details for study authors
Machado 2010
Methods Prospective cohort study
Participants 42 patients with epilepsy and depression
Interventions Sertraline 50 to 100 mg/day
Outcomes Cholesterol levels in responders versus non-responders
Notes Authors contacted for further data on depression scores and seizure frequency. No response
DSM-IV: Diagnostic and Statistical Manual of Mental Disorders IV
MADRS: Montgomery-Åsberg Depression Rating Scale
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D A T A A N D A N A L Y S E S
Comparison 1. Paroxetine versus doxepin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 > 50% reduction in depressive
symptoms
1 67 Risk Ratio (M-H, Fixed, 95% CI) 1.16 [0.88, 1.52]
2 Mean depression scores 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
2.1 HAMD scores 1 67 Mean Difference (IV, Fixed, 95% CI) 0.65 [-2.15, 3.45]
3 Withdrawals (any reason) 1 67 Risk Ratio (M-H, Fixed, 95% CI) 0.15 [0.01, 2.74]
4 Adverse effects 1 Risk Ratio (M-H, Fixed, 99% CI) Subtotals only
4.1 Blurred vision 1 67 Risk Ratio (M-H, Fixed, 99% CI) 0.34 [0.09, 1.32]
4.2 Dizziness 1 67 Risk Ratio (M-H, Fixed, 99% CI) 0.21 [0.03, 1.37]
4.3 Dry mouth 1 67 Risk Ratio (M-H, Fixed, 99% CI) 0.26 [0.06, 1.20]
4.4 Sleep disorders 1 67 Risk Ratio (M-H, Fixed, 99% CI) 0.32 [0.08, 1.20]
4.5 Urinary retention 1 67 Risk Ratio (M-H, Fixed, 99% CI) 0.34 [0.01, 21.99]
Comparison 2. Amitriptyline versus nomifensine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 > 50% reduction in depressive
symptoms
1 28 Risk Ratio (M-H, Fixed, 95% CI) 0.55 [0.28, 1.06]
Comparison 3. Venlafaxine versus no treatment controls
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 > 50% reduction in depressive
symptoms
1 64 Risk Ratio (M-H, Fixed, 95% CI) 3.25 [1.19, 8.90]
2 Mean depression scores -
HAMD
1 64 Mean Difference (IV, Fixed, 95% CI) -7.59 [-11.52, -3.66]
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Comparison 4. Citalopram (before and after)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mean depression scores
HAMD-21
2 176 Std. Mean Difference (Fixed, 95% CI) 1.17 [0.96, 1.38]
2 Mean monthly seizure frequency 2 Std. Mean Difference (Fixed, 95% CI) Totals not selected
Analysis 1.1. Comparison 1 Paroxetine versus doxepin, Outcome 1 > 50% reduction in depressive symptoms.
Review: Antidepressants for people with epilepsy and depression
Comparison: 1 Paroxetine versus doxepin
Outcome: 1 > 50% reduction in depressive symptoms
Study or subgroup Paroxetine Doxepin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Li 2005 27/33 24/34 100.0 % 1.16 [ 0.88, 1.52 ]
Total (95% CI) 33 34 100.0 % 1.16 [ 0.88, 1.52 ]
Total events: 27 (Paroxetine), 24 (Doxepin)
Heterogeneity: not applicable
Test for overall effect: Z = 1.07 (P = 0.28)
Test for subgroup differences: Not applicable
0.2 0.5 1 2 5
Favours doxepin Favours paroxetine
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Analysis 1.2. Comparison 1 Paroxetine versus doxepin, Outcome 2 Mean depression scores.
Review: Antidepressants for people with epilepsy and depression
Comparison: 1 Paroxetine versus doxepin
Outcome: 2 Mean depression scores
Study or subgroup Paroxetine Doxepin
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 HAMD scores
Li 2005 33 8.17 (6.25) 34 7.52 (5.42) 100.0 % 0.65 [ -2.15, 3.45 ]
Subtotal (95% CI) 33 34 100.0 % 0.65 [ -2.15, 3.45 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.45 (P = 0.65)
-100 -50 0 50 100
Favours paroxetine Favours doxepin
Analysis 1.3. Comparison 1 Paroxetine versus doxepin, Outcome 3 Withdrawals (any reason).
Review: Antidepressants for people with epilepsy and depression
Comparison: 1 Paroxetine versus doxepin
Outcome: 3 Withdrawals (any reason)
Study or subgroup Paroxetine Doxepin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Li 2005 0/33 3/34 100.0 % 0.15 [ 0.01, 2.74 ]
Total (95% CI) 33 34 100.0 % 0.15 [ 0.01, 2.74 ]
Total events: 0 (Paroxetine), 3 (Doxepin)
Heterogeneity: not applicable
Test for overall effect: Z = 1.28 (P = 0.20)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Doxepin Paroxetine
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Analysis 1.4. Comparison 1 Paroxetine versus doxepin, Outcome 4 Adverse effects.
Review: Antidepressants for people with epilepsy and depression
Comparison: 1 Paroxetine versus doxepin
Outcome: 4 Adverse effects
Study or subgroup Paroxetine Doxepin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
1 Blurred vision
Li 2005 4/33 12/34 100.0 % 0.34 [ 0.09, 1.32 ]
Subtotal (99% CI) 33 34 100.0 % 0.34 [ 0.09, 1.32 ]
Total events: 4 (Paroxetine), 12 (Doxepin)
Heterogeneity: not applicable
Test for overall effect: Z = 2.04 (P = 0.041)
2 Dizziness
Li 2005 2/33 10/34 100.0 % 0.21 [ 0.03, 1.37 ]
Subtotal (99% CI) 33 34 100.0 % 0.21 [ 0.03, 1.37 ]
Total events: 2 (Paroxetine), 10 (Doxepin)
Heterogeneity: not applicable
Test for overall effect: Z = 2.15 (P = 0.032)
3 Dry mouth
Li 2005 3/33 12/34 100.0 % 0.26 [ 0.06, 1.20 ]
Subtotal (99% CI) 33 34 100.0 % 0.26 [ 0.06, 1.20 ]
Total events: 3 (Paroxetine), 12 (Doxepin)
Heterogeneity: not applicable
Test for overall effect: Z = 2.27 (P = 0.023)
4 Sleep disorders
Li 2005 4/33 13/34 100.0 % 0.32 [ 0.08, 1.20 ]
Subtotal (99% CI) 33 34 100.0 % 0.32 [ 0.08, 1.20 ]
Total events: 4 (Paroxetine), 13 (Doxepin)
Heterogeneity: not applicable
Test for overall effect: Z = 2.22 (P = 0.026)
5 Urinary retention
Li 2005 0/33 1/34 100.0 % 0.34 [ 0.01, 21.99 ]
Subtotal (99% CI) 33 34 100.0 % 0.34 [ 0.01, 21.99 ]
Total events: 0 (Paroxetine), 1 (Doxepin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
0.01 0.1 1 10 100
Doxepin Paroxetine
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Analysis 2.1. Comparison 2 Amitriptyline versus nomifensine, Outcome 1 > 50% reduction in depressive
symptoms.
Review: Antidepressants for people with epilepsy and depression
Comparison: 2 Amitriptyline versus nomifensine
Outcome: 1 > 50% reduction in depressive symptoms
Study or subgroup Amitriptyline Nomifensine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Robertson 1985 6/14 11/14 100.0 % 0.55 [ 0.28, 1.06 ]
Total (95% CI) 14 14 100.0 % 0.55 [ 0.28, 1.06 ]
Total events: 6 (Amitriptyline), 11 (Nomifensine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.79 (P = 0.074)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours nomifensine Favours amitriptyline
Analysis 3.1. Comparison 3 Venlafaxine versus no treatment controls, Outcome 1 > 50% reduction in
depressive symptoms.
Review: Antidepressants for people with epilepsy and depression
Comparison: 3 Venlafaxine versus no treatment controls
Outcome: 1 > 50% reduction in depressive symptoms
Study or subgroup Venlafaxine No treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Zhu 2004 13/32 4/32 100.0 % 3.25 [ 1.19, 8.90 ]
Total (95% CI) 32 32 100.0 % 3.25 [ 1.19, 8.90 ]
Total events: 13 (Venlafaxine), 4 (No treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 2.29 (P = 0.022)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours control Favours venlafaxine
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Analysis 3.2. Comparison 3 Venlafaxine versus no treatment controls, Outcome 2 Mean depression scores -
HAMD.
Review: Antidepressants for people with epilepsy and depression
Comparison: 3 Venlafaxine versus no treatment controls
Outcome: 2 Mean depression scores - HAMD
Study or subgroup Venlafaxine No treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Zhu 2004 32 17.35 (7.93) 32 24.94 (8.12) 100.0 % -7.59 [ -11.52, -3.66 ]
Total (95% CI) 32 32 100.0 % -7.59 [ -11.52, -3.66 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.78 (P = 0.00016)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours venlafaxine Favours no treatment
Analysis 4.1. Comparison 4 Citalopram (before and after), Outcome 1 Mean depression scores HAMD-21.
Review: Antidepressants for people with epilepsy and depression
Comparison: 4 Citalopram (before and after)
Outcome: 1 Mean depression scores HAMD-21
Study or subgroup Before After
Std. Mean
Difference
(SE)
Std.
Mean
Difference Weight
Std.
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
Hovorka 2000 43 43 1.32 (0.148) 51.3 % 1.32 [ 1.03, 1.61 ]
Specchio 2004 45 45 1.01 (0.152) 48.7 % 1.01 [ 0.71, 1.31 ]
Total (95% CI) 88 88 100.0 % 1.17 [ 0.96, 1.38 ]
Heterogeneity: Chi2 = 2.14, df = 1 (P = 0.14); I2 =53%
Test for overall effect: Z = 11.03 (P < 0.00001)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Poorer outcome Improvement in outcome
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Analysis 4.2. Comparison 4 Citalopram (before and after), Outcome 2 Mean monthly seizure frequency.
Review: Antidepressants for people with epilepsy and depression
Comparison: 4 Citalopram (before and after)
Outcome: 2 Mean monthly seizure frequency
Study or subgroup
Std. Mean
Difference
(SE)
Std.
Mean
Difference
Std.
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
Hovorka 2000 0.0339 (0.135) 0.03 [ -0.23, 0.30 ]
Specchio 2004 0.4962 (0.1472) 0.50 [ 0.21, 0.78 ]
-4 -2 0 2 4
Poorer outcome Improvement in outcome
A D D I T I O N A L T A B L E S
Table 1. Risk of bias scale parameters
1 Low risk 2 3 4 5 High risk
Confounding All important1 con-
founders considered
2
and suitablemethod
of adjustment3 em-
ployed. Out-
come unlikely to be
affected
Most important
4 confounders con-
sidered and suit-
able method of ad-
justment employed.
Outcome unlikely
to be affected
Some confounders
5 considered and
full or partial ad-
justment employed
6. Possible implica-
tion for outcome
Some con-
founders considered
and no adjustment
employed. Likely to
affect outcome
No important con-
founders considered
and no adjustment
employed. Likely to
affect outcome
Blinding Assessors blinded to
participant’s drug
regime and partic-
ipants blinded to
drug regime. Out-
come unlikely to be
affected
Assessors blinded to
participant’s
drug regime. Out-
come unlikely to be
affected
Partial blinding7 in-
volved in study. Pos-
sible implication for
outcome
Partial or no blind-
ing involved
in study. Outcome
likely to be affected
No blinding
involved in study.
Outcome likely to
be affected
Incomplete
outcome data
No missing
data and/or appro-
priate analysis8 used
to deal with missing
data. Unlikely to af-
fect outcome
Smaller amount (<
25%) of miss-
ing data with rea-
sons given, balanced
across groups. Un-
likely to affect out-
Larger amount of
miss-
ing data (> 25%)
with or without rea-
sons given, balanced
across groups. Pos-
Larger
amount (> 25%) of
missing data, imbal-
ance across groups.
Outcome likely to
be affected
No information
provided regarding
missing data. Likely
to affect outcome
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Table 1. Risk of bias scale parameters (Continued)
come sible implication for
outcome
Selective outcome
reporting
A pri-
ori outcomes mea-
sured, analysed and
reported in main re-
port. Protocol avail-
able. Unlikely to af-
fect outcome
A priori outcomes
measured, anal-
ysed and reported in
main report9. Pro-
tocol not available.
Unlikely to affect
outcomes
Limited in-
formation regarding
a priori outcomes
and measures. Pos-
sible implication for
outcome
Outcomes mea-
sured but not anal-
ysed or reported
Out-
comesmeasured but
not analysed or re-
ported and clini-
cal judgement in-
fers the presence of
an unreported mea-
sured outcome10
Other bias No bias identified Bias identified. Un-
likely to affect out-
come
Bias identified. Pos-
sible implication for
outcome
Bias
identified. Likely to
affect outcome
Bias identified. Ex-
tremely likely to af-
fect outcome
1Important confounders include:
• mean age;
• epilepsy type;
• mean duration of epilepsy;
• location of epilepsy;
• mean baseline seizure frequency;
• mean baseline depression score.
2Reported demographic information and other confounders.
3Matching scores, multiple regression, analysis of co-variance, stratification.
4At least four out of six of important confounders including: mean baseline depression score and mean baseline seizure frequency.
5At least two out of six of the important confounders.
6Full adjustment of confounding variables, e.g. see footnote 2, or partial adjustment, e.g. researchers select limited number of variables
to adjust for.
7Assessors of outcome are only blinded to certain groups, e.g. blinded to intervention group but not controls.
8Intention-to-treat analysis.
9An a priori statement is made in the methods section of the main report regarding measurement and analysis of outcome.
10For example, failure to report full-scale depression score when all other indices are reported.
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A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MeSH descriptor: [Depression] explode all trees
#2 MeSH descriptor: [Depressive Disorder] explode all trees
#3 depression* or depressive*:ti,ab,kw (Word variations have been searched)
#4 “respiratory depression”:ti,ab,kw (Word variations have been searched)
#5 (#1 or #2 or #3) not #4
#6 MeSH descriptor: [Antidepressive Agents] explode all trees
#7 (antidepressant or antidepressive or “af 1161” or “ba 34276” or “bc 105” or “brl 29060” or “brl 29060” or “cl 67772”
or “cp 15467 61” or “du 23000” or “fg 7051” or “ici 58834” or “l deprenyl” or “leo 640” or “lilly 110140” or “lu 10 171” or
“ma 1291” or “nsc 16895” or “org gb 94” or “r 55667” or “ro 11 1163” or “trans 2 phenylcyclopropylamine” or “ym 35 995” or
“ym 992” or “zk 62711” or *amitriptyline or *doxepin or *moclobemide or *nortriptyline or *phenylethylhydrazine or *sertraline
or *trimip or *trimipramine or *tripramine or *tryptophan or abilify or adapin or adaptol or adderall or agomelatine or aiglonyl or
allegron or altruline or amfebutamone or amineptine or amineurin or amisulpride or amitrip or amitriptylin* or amitrol or amiz?l or
amoxapine or amphetamine or anafranil or anapsique or aponal or ardeydorm or ardeytropin or aremis or arima or aripiprazole or
arminol or aropax or asenapine or asendin or astyl or atomoxetine or auror?x or aventyl or axiomin or benactyzine or benzeneacetic acid
or besitran or bolvidon or bosnyl or brofaramine or bupropion or buspar or buspirone or butriptyline or carbamazepine or celexa or
chlomipramine or chlorgyline or cipralex or cipramil or citalopram or clomipramine or clorgilin* or clorgyline or concerta or cymbalta
or cytalopram or dalcipran or damilen or de*methylimipramine or deanol or defanyl or deftan or deman?l or demolox or depakote
or deponerton or deprax or deprenorm or deprilept or deptran or desidox or desiflu or desipramine or desisulpid or desitriptyline or
desmethylamitriptylin or desmethylloxapine or desvenlafaxine or desyrel or dexedrine or dexmethylphenidate or dextroamphetamine
or dibencycladine or digton or dilithium carbonate or dimethylaminoethanol or dimethylethanolamine or dogmatil or dolmatil or
domical or doneurin or dosulepin or dothiepin or doxepia or doxepin* or duloxetine or dumirox or edronax or ef*exor or eglonyl
or ekilid or elavil or eldepryl or eldoral or emovit or emsam or endep or escitalopram or eskalith or espadox or espiride or etonin or
etoperidone or evadene or favarin or fenelzin or feprapax or feraken or fevarin or floxyfral or fluoxetin* or fluvoxadura or fluvoxamin*
or focalin or gam?nil or gladem or guastil or herphonal or hydiphen or imidobenzyle or imipramine or imizin or insidon or iprazid
or iprindole or iproniazid or isocarboxazid or ixel or janimine or jatrosom or lamictal or lamotrigine or laroxyl or lebopride or lentizol
or lerivon or lexapro or lisdexamfetamine or lithane or lithium or lithobid or lofepramine or lomont or lopramine or lubazodone or
lucidil or ludiomil or lustral or luvox or lyphan or manerix or maprolu or maprotilin* or mareen or marplan or melitracen or meresa or
meridia or methylphenidate or mianserin or micalith or midalcipran or milnacepra* or mirpan or mirtazapine or moclamine or moclix
or moclob?mide or moclobemid* or moclobeta or moclodura or moclonorm or modal or molipaxin or nardelzine or nardil or naturruhe
or nefadar or nefazodone or neogama or nialamide or norfenazin or norpramin or nortrilen or norval or novoprotect or olanzapine
or opipramol or optimax or oxitriptan or pamelor or parnate or paroxetine or paxil or paxtibi or pertofran* or pertrofran or petylyl
or phenelzine or phenethylhydrazine or pirazidol or pirlindole or pizotifen or pizotyline or polomigran or pontiride or pramolan or
priadel or pristiq or prondol or prothiaden or protriptyline or prozac or prudoxin or pryleugan or psicocen or psymion or quetiapine
or quilinorm* or quipazine or quitaxon or quomen or r55667 or reboxetine or reductil or remeron or rhotrimine or rimoc or ritalin
or ritanserin or rolipram or sandomigran or saphris or sarafem or saroten or sarotex or savella or sealdin or sediel or selegiline or sendis
or seroquel or seroxat or serzone or sibutramine or sin*quan or solian or stangyl or strattera or sulp or sulpiride or sulpitil or sulpivert
or sulpor or surmontil or sycrest or symbyax or synedil or syneudon or tandospirone or tegretol or tepavil or thombran or tianeptine
or tofranil or toledomin or tolvon or tonibral or tradozone or tramadol or tramal or transamine or tranylcypromine or trazodon* or
trimeprimin* or trimidura or trimineurin or triptafen or trittico or trofan or tryptacin or tryptan or tryptanol or tryptine or tryptizol
or tyrima or ultram or valdoxan or valproic acid or venlafaxine or viibryd or vilazodone or viloxazine or vivactil or vivalan or vyvanse or
wellbutrin or xepin or yentreve or zelapar or zimelidine or zispin or zoloft or zonalon or zyban or zyntabac):ti,ab,kw (Word variations
have been searched)
#8 #6 or #7
#9 (epilep* or seizure* or convuls*):ti,ab,kw (Word variations have been searched)
#10 MeSH descriptor: [Epilepsy] explode all trees
#11 MeSH descriptor: [Seizures] explode all trees
#12 (#9 or #10 or #11) in Trials
#13 #5 and #8 and #12
#14 MeSH descriptor: [Electroconvulsive Therapy] explode all trees
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#15 #13 not #14
Appendix 2. MEDLINE search strategy
1. (validation studies or clinical trial or clinical trial phase i or clinical trial phase ii or clinical trial phase iii or clinical trial phase iv or
comparative study or evaluation studies or multicenter study).pt.
2. ((observation$ or cohort or case$ or cross?section$ or “cross section$” or “time-series” or “time series” or “before and after” or
“before-and-after” or retrospective) adj2 (study or trial or method)).mp.
3. (randomized controlled trial or controlled clinical trial).pt. or (randomized or placebo or randomly).ab.
4. clinical trials as topic.sh.
5. trial.ti.
6. 1 or 2 or 3 or 4 or 5
7. exp animals/ not humans.sh.
8. 6 not 7
9. exp Depression/ or exp Depressive Disorder/ or exp Dysthymic Disorder/ or (depression$ or depressive$).tw.
10. “respiratory depression”.tw.
11. 9 not 10
12. exp Antidepressive Agents/ or anti?depress$.tw.
13. (“af 1161” or “bc 105” or “brl 29060” or “cl 67772” or “cp 15467 61” or “du 23000” or “ici 58834” or “leo 640” or “lilly 110140”
or “ma 1291” or “nsc 16895” or “org gb 94” or “r 55667” or “ro 11-1163” or “trans 2 phenylcyclopropylamine” or “ym-35,995” or
“zk 62711” or abilify or adapin or adaptol or adderall or af?1161 or agomelatine or aiglonyl or allegron or altruline or amfebutamone
or amineptine or amineurin or amisulpride or amitrip or amitriptylin$ or amitrol or amiz?l or amoxapine or amphetamine or anafranil
or anapsique or apo?doxepin or apo?moclob?mide or apo?nortriptyline or apo?sertraline or apo?trimip or apoamitriptyline or aponal
or ardeydorm or ardeytropin or aremis or arima or aripiprazole or arminol or aropax or asenapine or asendin or astyl or atomoxetine
or auror?x or aventyl or axiomin or ba?34276 or bc?105 or benactyzine or benzeneacetic acid or besitran or beta?phenylethylhydrazine
or bolvidon or bosnyl or brl?29060 or brofaramine or bupropion or buspar or buspirone or butriptyline or carbamazepine or celexa or
chlomipramine or chlorgyline or cipralex or cipramil or citalopram or cl?67772 or clomipramine or clorgilin$ or clorgyline or concerta
or cp?15467?61 or cymbalta or cytalopram or dalcipran or damilen or de?methylimipramine or deanol or defanyl or deftan or deman?l
or demolox or depakote or deponerton or deprax or deprenorm or deprilept or deptran or desidox or desiflu or desipramine or desisulpid
or desitriptyline or desmethylamitriptylin or desmethylloxapine or desvenlafaxine or desyrel or dexedrine or dexmethylphenidate or
dextroamphetamine or dibencycladine or digton or dilithium carbonate or dimethylaminoethanol or dimethylethanolamine or dogmatil
or dolmatil or domical or doneurin or dosulepin or dothiepin or doxepia or doxepin$ or du?23000 or duloxetine or dumirox or edronax
or ef?exor or eglonyl or ekilid or elavil or eldepryl or eldoral or emovit or emsam or endep or escitalopram or eskalith or espadox or
espiride or etonin or etoperidone or evadene or favarin or fenelzin or feprapax or feraken or fevarin or fg?7051 or floxyfral or fluoxetin$
or fluvoxadura or fluvoxamin$ or focalin or gam?nil or gen?nortriptyline or gen?sertraline or gladem or guastil or herphonal or hydiphen
or ici?58834 or imidobenzyle or imipramine or imizin or insidon or iprazid or iprindole or iproniazid or isocarboxazid or ixel or janimine
or jatrosom or lamictal or lamotrigine or laroxyl or l-deprenyl or lebopride or lentizol or lerivon or levo?tryptophan or lexapro or lilly?
110140 or lisdexamfetamine or lithane or lithium or lithobid or lofepramine or lomont or lopramine or l-tryptophan or lu?10?171 or
lubazodone or lucidil or ludiomil or lustral or luvox or lyphan or ma?1291 or manerix or maprolu or maprotilin$ or mareen or marplan
or melitracen or meresa or meridia or methylphenidate or mianserin or micalith or midalcipran or milnacepram or milnacipra? or
mirpan or mirtazapine or moclamine or moclix or moclob?mide or moclobemid$ or moclobeta or moclodura or moclonorm or modal
or molipaxin or nardelzine or nardil or naturruhe or nefadar or nefazodone or neogama or nialamide or nor?nortriptyline or norfenazin
or norpramin or nortrilen or nortriptyline or norval or novo?doxepin or novo?moclob?mide or novo?nortriptyline or novo?sertraline or
novo?tripramine or novoprotect or nsc?16895 or nu?moclob?mide or nu?nortriptyline or nu?trimipramine or nu?tripramine or numo?
moclob?mide or olanzapine or opipramol or optimax or oxitriptan or pamelor or parnate or paroxetine or paxil or paxtibi or pert?
ofran$ or petylyl or phenelzine or phenethylhydrazine or phenylethylhydrazine or pirazidol or pirlindole or pizotifen or pizotyline or
pms?moclob?mide or pms?nortriptyline or pms?tryptophan or polomigran or pontiride or pramolan or priadel or pristiq or prondol or
prothiaden or protriptyline or prozac or prudoxin or pryleugan or psicocen or psymion or quetiapine or quilinorm?retard or quipazine
or quitaxon or quomen or r55667 or r-55667 or ratio?nortriptyline or ratio?sertraline or ratio?tryptophan or reboxetine or reductil
or remeron or rhotrimine or rhoxal?sertraline or rimoc or ritalin or ritanserin or ro-11-1163 or rolipram or sandomigran or saphris
or sarafem or saroten or sarotex or savella or sealdin or sediel or selegiline or sendis or seroquel or seroxat or sertraline or serzone or
sibutramine or sin?quan or solian or stangyl or strattera or sulp or sulpiride or sulpitil or sulpivert or sulpor or surmontil or sycrest or
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symbyax or synedil or syneudon or tandospirone or tegretol or tepavil or thombran or tianeptine or tofranil or toledomin or tolvon
or tonibral or tradozone or tramadol or tramal or trans-2-phenylcyclopropylamine or transamine or tranylcypromine or trazodon$ or
trim?pr?min$ or trimidura or trimineurin or trimip or tripramine or triptafen or trittico or trofan or tryptacin or tryptan or tryptanol or
tryptine or tryptizol or tryptophan or tyrima or ultram or valdoxan or valproic acid or venlafaxine or viibryd or vilazodone or viloxazine
or vivactil or vivalan or vyvanse or wellbutrin or xepin or yentreve or ym-992 or zelapar or zimelidine or zispin or zk?62711 or zoloft
or zonalon or zyban or zyntabac).mp.
14. 12 or 13
15. exp Epilepsy/
16. exp Seizures/
17. (epilep$ or seizure$ or convuls$).tw.
18. 15 or 16 or 17
19. exp Pre-Eclampsia/ or exp Eclampsia/
20. 18 not 19
21. 8 and 11 and 14 and 20
22. exp Electroconvulsive Therapy/
23. 21 not 22
24. 23 not case reports.pt.
Appendix 3. Extended ’Risk of bias’ tool for non-randomised studies
Studies for which the ’Risk of bias’ tool is intended
Only suitable for ’cohort-like’ studies, individually or cluster-allocated. This can include secondary analyses of clinical databases
providing the analysis is clearly structured as a comparison of control and intervention participants:
Individually allocated study designs
• Randomised controlled trial
• Quasi-randomised controlled trial
• Non-randomised controlled trial
• Controlled before and after study (not common use of this label, see controlled cohort before and after study below)
• Prospective cohort study
• Retrospective cohort study
Cluster-allocated study designs
• Cluster randomised controlled trial
• Cluster quasi-randomised controlled trial
• Cluster non-randomised controlled trial
• Controlled interrupted time series
• Controlled cohort before and after study
Assessment of risk of bias
Issues when using the modified ’Risk of bias’ tool to assess cohort-like non-randomised studies:
• Follows principle for existing Cochrane Collaboration tool for risk of bias: score judgement and provide information (preferably
direct quote) to support judgement.
• Modified ’Risk of bias’ tool includes an additional item on confounding.
• Five-point scale for some items (to distinguish ’unclear’ from intermediate risk of bias).
• Keep in mind the general philosophy - assessment is not about whether researchers could have done better but about risk of bias;
the assessment tool must be used in a standard way whatever the difficulty/circumstances of investigating the research question of
interest and whatever study design features were used.
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• Use of a five-point scale is uncharted territory
• Anchors for five-point scale: ’1/No/low risk’ of bias should correspond to a high quality RCT. ’5/high risk’ of bias should
correspond to a risk of bias that means the findings should not be considered (too risky, too much bias, more likely to mislead than
inform).
Sequence generation
• Low/high/unclear risk of bias item.
• Always high risk of bias (not random) for a non-randomised study.
• Might argue that this item is redundant for non-randomised studies since they are always at high risk of bias - but important to
include in ’Risk of bias’ table (’level playing field’ argument).
Allocation concealment
• Low/high/unclear risk of bias item.
• Potentially low risk of bias for a non-randomised study, e.g. quasi-randomised (high risk of bias due to sequence generation) but
concealed (author judges that the people making decisions about including participants did not know how allocation was being done,
e.g. odd/even date of birth/hospital number).
Risk of bias from confounding (additional item for non-randomised studies; assess for each outcome)
• Assumes a prespecified list of potential confounders defined in the protocol for the systematic review.
• Low (1) / 2 / 3 / 4 / high (5) / unclear risk of bias item.
• Judgement needs to factor in (see ’worksheet’):
◦ proportion of confounders (from pre-specified list) that were considered;
◦ whether most important confounders (from pre-specified list) were considered;
◦ resolution/precision with which confounders were measured;
◦ extent of imbalance between groups at baseline;
◦ care with which adjustment was done (typically a judgement about the statistical modelling carried out by authors).
• Low risk of bias requires that all important confounders are balanced at baseline, i.e.:
◦ not primarily/not only a statistical judgement; or
◦ measured ’well’ and ’carefully’ controlled for in the analysis.
We have provided an optional ’worksheet’ to help reviewers to focus on the task (rows = confounders and columns = factors to consider).
Authors should make a risk of bias judgement about each factor first and then combine these (by eyeballing rather than quantitatively)
to make the judgement in the main ’Risk of bias’ table.
Risk of bias from lack of blinding (assess for each outcome, as per the existing risk of bias tool)
• Low (1) / 2 / 3 / 4 / high (5) / unclear risk of bias item.
• Judgement needs to factor in:
◦ nature of outcome (subjective/objective; source of information);
◦ who was/was not blinded and the risk that those who were not blinded could introduce performance or detection bias.
Risk of bias from incomplete outcome data (assess for each outcome, as per the existing risk of bias tool)
• Low (1) / 2 / 3 / 4 / high (5) / unclear risk of bias item.
• Judgement needs to factor in:
◦ reasons for missing data;
◦ whether amount of missing data balanced across groups, with similar reasons;
◦ whether group comparison appropriate (e.g. ’analysed in allocated group’ issue).
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Risk of bias from selective reporting (assess for each outcome)
• More wide-ranging than existing assessment recommendation. Key issue is whether outcomes were clearly defined, and methods
of analysis were pre-specified and adhered to.
• Low (1) / 2 / 3 / 4 / high (5) / unclear risk of bias item.
• Judgement needs to factor in:
◦ existing risk of bias guidance on selective outcome reporting;
◦ also, extent to which analyses (and potentially other choices) could have been manipulated to bias the findings reported,
e.g. choice of method of model fitting, potential confounders considered/included;
◦ look for evidence that there was a protocol in advance of doing any analysis/obtaining the data (difficult unless explicitly
reported); non-randomised studies are very different from RCTs. RCTs must have a protocol in advance of starting to recruit (for
research ethics committee/institutional review board/other regulatory approval); non-randomised studies need not (especially older
studies);
◦ hence, separate yes/no items asking reviewers whether they think the researchers had a prespecified protocol and analysis
plan?
Appendix 4. Assessment of confounding variables
Assessment of how researchers dealt with confounding
Method for identifying relevant confounders described by researchers: Yes No
If yes, describe the method used:
Relevant confounders described: Yes No
List confounders described below
Method used for controlling for confounding
At design stage: matching by characteristics of subjects (see below for matching by propensity score)
Variables on which subjects matched: ………………………………….
…………………………………
…………………………………
…………………………………
At analysis stage: stratification
multivariable regression
propensity scores (matching)
propensity scores (multivariable regression)
Describe confounders controlled for below
Confounders described by researchers
Enter/preprint prespecified list of confounders (rank order in importance? Important in bold?)
Tick (yes/no judgement) if confounder considered by the researchers [Cons’d?]
Score (1 to 5) precision with which confounder measured
Score (1 to 5) imbalance between groups
Score (1 to 5) care with which adjustment for confounder was carried out
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Confounder Considered Precision Imbalance Adjustment
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